Document:

<PAGE>
                                                                    EXHIBIT 10.1

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

                        SETTLEMENT AND LICENSE AGREEMENT

      This Settlement and License Agreement ("AGREEMENT") is made and entered by
and among Biogen Idec Inc., a Delaware corporation ("Biogen Idec"), Corixa
Corporation, a Delaware Corporation ("Corixa"), Coulter Pharmaceutical, Inc., a
Delaware Corporation ("Coulter"), The Regents of the University of Michigan, a
constitutional corporation of the State of Michigan ("Michigan"), and SmithKline
Beecham Corporation d/b/a GlaxoSmithKline, a Pennsylvania Corporation ("GSK")
(collectively the "PARTIES"). The EFFECTIVE DATE of this AGREEMENT is February
27, 2004.

                                    RECITALS

      1. Certain disputes and controversies have arisen between the PARTIES
relating to the claims, counter-claims, cross-claims, and demands set forth in
the following civil actions ("THE LAWSUITS"):

            a. Southern District of California Case No. 01-CV-1637 IEG (RBB): On
September 10, 2001, IDEC Pharmaceuticals Corp. ("IDEC") filed a complaint in the
Southern District of California against Corixa, Coulter and Michigan for a
declaratory judgment of patent non-infringement and invalidity of U.S. Patents
6,015,542, 6,090,365, 5,595,721, 5,843,398, 6,251,362, and 6,022,521. This was
assigned Case No. 01-CV-1637 IEG (RBB). On September 12, 2001, IDEC filed a
First Amended Complaint, adding a claim for declaratory judgment of patent
non-infringement and invalidity of U.S. Patent 6,287,537. On February 13, 2002,
Corixa, Coulter, Michigan and GSK filed a counterclaim alleging patent
infringement of U.S. Patents 5,595,721, 6,015,542, and 6,090,365. On August 13,
2002, Corixa, Coulter, GSK and Michigan amended their counterclaim to include a
claim for infringement of U.S. Patent 6,287,537.

            b. District of Delaware Case No. 01-615; Southern District of
California Case 02-CV-0508 IEG (RBB): On September 12, 2001, Corixa, Coulter,
and GSK filed a complaint in the District Court of Delaware against IDEC
alleging patent infringement and for a declaratory judgment of infringement of
U.S. Patents 5,595,721, 6,015,542, and 6,090,365. This was assigned Case No.
01-615. On September 28, 2001, Corixa, Coulter, Michigan and GSK filed an
Amended Complaint, adding Michigan as a plaintiff. Pursuant to a motion to
transfer, this case was transferred to the Southern District of California and
assigned Case No. 02-CV-0508 IEG (RBB). The case was consolidated with Case No.
01-CV-1637 IEG (RBB), and pursuant to court order, was then referred to as Case
No. 01-CV-1637 IEG (RBB). Corixa, Coulter, GSK and Michigan filed an Amended
Complaint, adding a cause of action for patent infringement of U.S. Patent No.
6,287,537. IDEC has filed counterclaims for declaratory judgment of patent
non-infringement and invalidity of U.S. Patents 6,015,542, 6,090,365, 5,595,721,
and 6,287,537.

<PAGE>

            c. Southern District of California Case No. 03-CV-00380 IEG (RBB):
On February 25, 2003, IDEC filed a complaint in the Southern District of
California against Corixa, Coulter and GSK for infringement of U.S. Reissue
Patent No. RE 38,008. This was assigned Case No. 03-CV-00380 IEG (RBB). On April
1, 2003, GSK filed a counterclaim for a declaratory judgment of
non-infringement, invalidity, unenforceability and for interference with
contractual relations. The cause of action for interference with contractual
relations was dismissed by the Court on September 30, 2003. On August 18, 2003,
Corixa and Coulter filed a counterclaim for a declaratory judgment of
non-infringement, invalidity and unenforceability of U.S. Reissue Patent No. RE
38,008.

            d. Southern District of California Case No. 03-CV-1093 IEG (RBB): On
June 2, 2003, IDEC filed a complaint against Corixa, Coulter, Michigan and GSK
for declaratory judgment of non-infringement, invalidity and unenforceability of
U.S. Patent No. 6,565,827. In December, 2003, Corixa, Coulter, Michigan and GSK
provided a covenant not to sue Biogen Idec for infringement as to any claim of
the `827 patent:

            "Patentees Corixa Corporation, Coulter Pharmaceuticals, the
            University of Michigan and SmithKline Beecham d/b/a GlaxoSmithKline
            unconditionally agree not to sue Biogen IDEC for infringement as to
            any claim of the `827 patent based upon the Zevalin(TM) or the
            Zevalin(TM) Therapeutic Regimen as previously or currently
            manufactured and sold or any Zevalin(TM) or the Zevalin(TM)
            Therapeutic Regimen as currently approved by the FDA. By this,
            Patentees' representation to Biogen IDEC extends to infringement for
            any current or past off label use."

Based upon this covenant not to sue, Biogen Idec dismissed the action without
prejudice. This covenant not to sue is memorialized in the following letters:
the December 11, 2003, letter from William G. Gaede (counsel for Corixa,
Coulter, and Michigan) to James J. Elacqua (counsel for Biogen Idec), and in the
December 15, 2003, and December 16, 2003, letters from Martin I. Fuchs (counsel
for GSK) to F.T. Alexandra Mahaney (counsel for Biogen Idec), all of which are
attached to the Notice of Voluntary Dismissal Without Prejudice filed in this
case (the "'827 COVENANT NOT TO SUE"). Notwithstanding this AGREEMENT, this '827
COVENANT NOT TO SUE remains in effect.

      2. On November 12, 2003, Biogen, Inc. merged with a wholly owned
subsidiary of IDEC and IDEC changed its name to "Biogen Idec Inc." On or about
November 13, 2003, a Notice of Name Change was filed in THE LAWSUITS changing
the name of IDEC to Biogen Idec.

      3. Following a course of negotiations and mediation among the PARTIES
hereto and their respective counsel, the PARTIES on February 27, 2004, agreed to
settle and compromise all disputes, claims and controversies among them relating
to the PATENTS IN SUIT, including all claims, counter-claims and cross-claims
that were asserted in THE LAWSUITS by any of the PARTIES.

                                       2

<PAGE>

                                   DEFINITIONS

      1. "THE KAMINSKI PATENT FAMILY" shall mean (i) U.S. Patents No. 6,015,542,
6,090,365, 5,595,721, 5,843,398, 6,287,537, and 6,565,827; (ii) any patents,
including, without limitation, any United States, international or foreign
national or regional patents that issue from counterparts applications,
continuations, continuations-in-part, divisionals or continued prosecution or
renewal applications of any patent application from which any of the foregoing
patents set forth in subsection (i) claims priority; and (iii) any patents,
including, without limitation, any United States, international or foreign
national or regional patents resulting from counterpart applications, reissues,
reexaminations, extensions, interferences or oppositions of any of the
foregoing.

      2. "THE WAHL PATENT FAMILY" shall mean (i) U.S. Patents No. 6,251,362, and
6,022,521; (ii) any patents, including, without limitation, any United States,
international or foreign national or regional patents that issue from
counterparts applications, continuations, continuations-in-part, divisionals or
continued prosecution or renewal applications of any patent application from
which any of the foregoing patents set forth in subsection (i) claims priority;
and (iii) any patents, including, without limitation, any United States,
international or foreign national or regional patents resulting from counterpart
applications, reissues, reexaminations, extensions, interferences or oppositions
of any of the foregoing.

      3. "THE NEORX PATENT FAMILY" shall mean (i) U.S. Reissue Patent No. RE
38,008; (ii) any patents, including, without limitation, any United States,
international or foreign national or regional patents that issue from
counterparts applications, continuations, continuations-in-part, divisionals or
continued prosecution or renewal applications of any patent application from
which any of the foregoing patents set forth in subsection (i) claims priority;
and (iii) any patents, including, without limitation, any United States,
international or foreign national or regional patents resulting from counterpart
applications, reissues, reexaminations, extensions, interferences or oppositions
of any of the foregoing.

      4. "PATENTS IN SUIT" shall mean THE KAMINSKI PATENT

      5. FAMILY, THE WAHL PATENT FAMILY and THE NEORX PATENT FAMILY.

      6. "ZEVALIN KITS" refers to: (a) any kit containing Ibritumomab Tiuxetan
for the preparation of Indium-111 Ibritumomab Tiuxetan and Yttrium-90
Ibritumomab Tiuxetan as currently formulated and approved by the FDA, together
with any [*] thereon related to the treatment of any [*]; (b) any modification
to the kit described in subpart (a) resulting from a [*] to the [*], or from a
separate [*] that could have been [*] with the [*] as a [*] to the [*] as
determined by the then-current [*] governing the [*] of [*] and [*]; and (c) any
modification to the kit described in subpart (a) that consists of [*] the [*] as
currently approved into [*] and/or [*] to [*] [*] of the [*] (such as [*] to [*]
Indium-111 Ibritumomab Tiuxetan). ZEVALIN KITS does not include: (a) the use of
ZEVALIN KITS for any indication other than [*]; or (b) any products requiring
the [*] of a [*].

      7. "NET SALES" shall mean the gross invoiced sales prices charged for all
ZEVALIN KITS sold by Biogen Idec, its AFFILIATES or ZEVALIN SUBLICENSEES (but
with respect to

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       3

<PAGE>

ZEVALIN SUBLICENSEES, only in the circumstances described in the last sentence
of definition 11 below) during a CALENDAR YEAR for ultimate use in the United
States, after deduction of the following items:

            a.  trade, quantity, allowances or cash discounts;

            b.  amounts repaid or credited by reason of rejection or return of
                previously sold products, or for rebates or retroactive price
                reductions (including, without limitation, Medicaid, Medicare,
                government, commercial and similar types of rebates);

            c.  all taxes and other governmental charges levied on sale,
                delivery or use, as applicable (excluding income taxes of any
                kind);

            d.  transportation costs prepaid or allowed and costs of insurance
                in transit, customs duties, surcharges and other governmental
                charges, to the extent expressly set forth as part of the gross
                invoiced sales price to the THIRD PARTY;

            e.  except where redundant with amounts in subparagraph (b) above,
                credits or allowances given or made for wastage replacement; and

            f.  periodic adjustment of the provision determined in subsections
                (a) to (e) to reflect amounts actually incurred.

For the purposes of this NET SALES definition:

            (i) Any "sale" that occurs other than in an arm's-length transaction
for fair market value shall be deemed to have occurred at a NET SALES amount
equal to the average invoice price for the selling party, less the average
permissible deductions for sales occurring during that year for the selling
party in arm's-length transactions. If the selling party did not have any
arm's-length transactions for fair market value during that year, then such
sales shall be deemed to have occurred at a NET SALES amount equal to the fair
market value of ZEVALIN KITS at that stage of the distribution chain in the
United States, as determined by the price charged in arm's-length transactions
by other parties at such stage of the distribution chain in the United States
during such calendar year or other evidence of such fair market value.

            (ii) A "sale" is deemed to occur upon the earlier to occur of the
date the ZEVALIN KITS are shipped or the date of invoice to the purchaser of the
ZEVALIN KITS.

            (iii) A sale of ZEVALIN KITS among or between Biogen Idec and its
AFFILIATES for resale of such ZEVALIN KITS by Biogen Idec or any such AFFILIATE
shall not be considered a sale for purposes of this provision. In the case of
sales by Biogen Idec or any AFFILIATE to ZEVALIN SUBLICENSEES: (a) except as
expressly provided in the last sentence of definition 11, sales to the ZEVALIN
SUBLICENSEE shall constitute NET SALES (and the further resale of such ZEVALIN
KITS by the ZEVALIN SUBLICENSEE shall be omitted from NET SALES), and (b) in the
case described in the last sentence in definition 11 in which the resale by the
ZEVALIN SUBLICENSEE is included in NET SALES, then the sale of the ZEVALIN KIT
by Biogen Idec or any AFFILIATE to the ZEVALIN SUBLICENSEE shall be omitted from
NET SALES.

                                       4

<PAGE>

            (iv) A "sale" shall not include transfers or other distributions or
dispositions of ZEVALIN KITS, at no-charge, for pre-clinical, clinical or
regulatory purposes or to physicians or hospitals for promotional purposes or as
free goods supplied to indigent patients or in connection with compassionate use
or similar programs.

            (v) "Sales" shall also exclude sales of ZEVALIN KITS for ultimate
use in a country outside of the United States, noting that, in this regard, the
calculation of NET SALES shall exclude ZEVALIN KITS which are sold in the United
States for ultimate use in a country outside of the United States, but shall
include ZEVALIN KITS which are sold outside of the United States for ultimate
use in the United States where such use is intended and licensed by Biogen Idec
or its Affiliates.

            (vi) If Biogen Idec or any of its AFFILIATES or any ZEVALIN
SUBLICENSEES bundles the sale of ZEVALIN KITS with the sale of any other product
or service, the portion of the bundled price included in NET SALES shall be the
portion of such bundled price allocable to the fair value of the ZEVALIN KITS
relative to the fair value of the other elements of the bundled sale (determined
on the basis of what would have been charged by Biogen Idec or any such
AFFILIATE or ZEVALIN SUBLICENSEE to an unrelated purchaser in an arm's length
transaction).

            (vii) If Biogen Idec, its AFFILIATES or ZEVALIN SUBLICENSEES (to the
extent provided in the last sentence of definition 11) collect additional
payments from a purchasing party, calculated based upon sales of ZEVALIN KITS
which are in addition to, and where NET SALES have been calculated from, the
gross invoiced sales price to such purchasing party for such ZEVALIN KITS (e.g.,
in the form of royalties or comparable payments based on resales of ZEVALIN KITS
by such purchasing party), then such additional payments shall also be included
in calculating NET SALES as received.

      8. "THIRD PARTY(IES)" shall mean any person or entity other than a PARTY
to this AGREEMENT or their respective AFFILIATES or its or their SUBLICENSEES.

      9. "THE ASSERTED CLAIMS" mean claims 1-4, 8, 10, 14, 18, and 22 of U.S.
Patent 6,595,721; claims 1-3, 7-8 and 10 of U.S. Patent 6,015,542; claims 1-2,
4-5, 7, 19-20, and 23-27 of U.S. Patent No. 6,090,365; and claims 1, 3, 7-9, 11,
13, 15-16, 19-21, 23, 25, 27-28, 31-33, 35, 37, 39-41, 44-46, 48, 50 and 52 of
U.S. Patent 6,287,537.

      10. "AFFILIATES" shall mean with respect to any person or entity, any
other person or entity, which controls, is controlled by or is under common
control with such person or entity. A person or entity shall be regarded as in
control of another entity if it owns or controls, directly or indirectly, (i) in
the case of corporate entities at least fifty percent (50%) (or the maximum
ownership interest permitted by law, if less than 50%) of the equity securities
in the subject entity entitled to vote in the election of directors, and (ii) in
the case of an entity that is not a corporation, at least fifty percent (50%)
(or the maximum ownership interest permitted by law, if less than 50%) of the
equity securities or other ownership interests with the power to direct the
management and policies of such entity or entitled to elect the corresponding
management authority.

                                       5

<PAGE>

      11. "SUBLICENSEE" shall mean any entity or person to whom (i) Biogen Idec
has granted (whether before or after the EFFECTIVE DATE) a right to make, have
made, use, offer to sell, sell or import a product covered by any of THE
KAMINSKI PATENT FAMILY or THE WAHL PATENT FAMILY or (ii) Corixa, Coulter,
Michigan and GSK has granted (whether before or after the EFFECTIVE DATE) a
right to make, have made, use, offer to sell, sell or import a product covered
by any of THE NEORX PATENT FAMILY.

      12. "ZEVALIN SUBLICENSEE" shall mean any entity or person to whom Biogen
Idec has granted (whether before or after the EFFECTIVE DATE) a right to make,
use, sell, offer to sell or import the ZEVALIN KITS, but shall not include any
of the following: (a) any [*], [*] or [*] or facility to the extent it is a
recipient of ZEVALIN KITS for [*] and/or [*] to one or more [*]; (b) any [*] or
[*] health [*] to the extent it is a recipient of ZEVALIN KITS for [*] and/or
[*] to one or more [*]; and (c) any [*], [*], [*] health [*] to the extent [*]
or [*] [*], and/or [*] ZEVALIN to one or more [*]. Notwithstanding any provision
herein to the contrary, sales of ZEVALIN KITS by ZEVALIN SUBLICENSEES shall be
included within NET SALES only if the ZEVALIN SUBLICENSEE in question has
contractually agreed with [*] or an [*] to perform (whether itself or through
others), and is substantially responsible for, the [*] and [*] of the ZEVALIN
KITS; provided, however, that a party entering into a [*] or [*] with Biogen
Idec or an AFFILIATE in which Biogen Idec or the AFFILIATE [*] the [*] from the
ZEVALIN KITS is not intended to be construed as a ZEVALIN SUBLICENSEE for
purposes of the preceding sentence.

      13. "CALENDAR YEAR" shall mean the period from January 1st through
December 31st.

                                    AGREEMENT

            Now, therefore, in consideration of the mutual covenants and
agreements contained herein, the sufficiency of which is acknowledged, the
PARTIES agree as follows:

      1. DISMISSAL OF LAWSUITS: The PARTIES shall not pursue any further
proceedings in THE LAWSUITS and shall dismiss with prejudice all respective
claims, cross-claims and counterclaims pending in THE LAWSUITS. Within five days
of execution of this AGREEMENT, the PARTIES shall sign the two attached Notices
of Stipulated Dismissal With Prejudice Of All Claims And Counterclaims. Biogen
Idec shall cause these Stipulations to be filed with the Court, and shall
provide the other PARTIES with a filed-stamp copy of the Stipulations upon
receipt.

      2. PAYMENT: Upon execution of this AGREEMENT and in settlement of all
outstanding claims, Biogen Idec will pay to Corixa the sum of twenty million
United States dollars (U.S. $20 million) by wire transfer of immediately
available funds. Such payment shall become non-refundable and non-creditable
against any other amounts due under this AGREEMENT upon entry by the Court of
the Notices of Stipulated Dismissals described in paragraph 1 signed by all
PARTIES. Any wire transfer payments to Corixa under this Agreement shall be made
to the following account, or such other account as Corixa may hereafter
designate in writing:

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       6

<PAGE>

                           Bank             The Commerce Bank of Washington
                                            601 Union Street, Suite 3600
                                            Seattle, WA    98104
                           ABA Number       125008013
                           Account          Corixa Corporation
                           Account Number   [*]

      3. LICENSE GRANTS:

            3.1 LICENSE TO THE KAMINSKI PATENT FAMILY AND THE WAHL PATENT
FAMILY:

                  3.1.1 Corixa, Coulter, Michigan and GSK hereby each grant to
Biogen Idec a worldwide, irrevocable, non-exclusive license to THE KAMINSKI
PATENT FAMILY and THE WAHL PATENT FAMILY for any and all purposes.

                  3.1.2 The term of this license shall be from the EFFECTIVE
DATE of this AGREEMENT until the date of expiration of the last-to-expire patent
of THE KAMINSKI PATENT FAMILY and THE WAHL PATENT FAMILY.

                  3.1.3 Biogen Idec shall have the irrevocable right to grant
sublicenses to THE KAMINSKI PATENT FAMILY and THE WAHL PATENT FAMILY, provided
that Biogen Idec incorporates terms and conditions into its sublicense
agreements sufficient to enable Biogen Idec to comply with its obligations under
this AGREEMENT and the sublicensee expressly agrees to and accepts that the
terms and conditions of this AGREEMENT are binding upon it.

            3.2 LICENSE TO THE NEORX PATENT FAMILY:

                  3.2.1 Biogen Idec hereby grants to each of Corixa, Coulter and
GSK a worldwide, irrevocable, non-exclusive license to THE NEORX PATENT FAMILY
for any and all purposes.

                  3.2.2 The term of this license shall be from the EFFECTIVE
DATE of this AGREEMENT until the date of expiration of the last-to-expire patent
of THE NEORX PATENT FAMILY.

                  3.2.3 Corixa, Coulter and GSK shall have the irrevocable right
to grant sublicenses to THE NEORX PATENT FAMILY, provided that they incorporate
terms and conditions into their sublicense agreements sufficient to enable
Corixa, Coulter and GSK to comply with their obligations under this AGREEMENT
and the sublicensee expressly agrees to and accepts that the terms and
conditions of this AGREEMENT are binding upon it. Corixa, Coulter and GSK shall
each have the power to grant such sublicenses, subject to any separate agreement
among such parties.

      4. ROYALTY PAYMENTS:

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       7

<PAGE>

            4.1 One Time Sales-Based Milestone Payment: Biogen Idec will make a
one-time payment of [*] United States dollars (U.S. $[*]) to Corixa by wire
transfer of immediately available funds within forty-five days of the end of the
first CALENDAR YEAR in which NET SALES exceed the sum of [*] United States
dollars (U.S. $[*]) in that one CALENDAR YEAR, except as provided in paragraph
4.3 below. Such payment shall be non-refundable and non-creditable against any
other amounts due under this AGREEMENT.

            4.2 Royalty Payments: Biogen Idec will pay to Corixa a [*] royalty
on NET SALES occurring between [*], and [*], except as provided in paragraph 4.3
below. These royalty payments will be due within forty-five days after the end
of each CALENDAR YEAR during such period, except that the royalty payments with
respect to NET SALES during the first [*] days of [*] shall be made on or before
[*]. Without limitation, this royalty obligation does not apply to any revenues
obtained by Biogen Idec or its AFFILIATES or SUBLICENSEES on the sale of
Rituxan(R) in its non-radiolabeled form.

            4.3 Exceptions to Requirement of Royalty Payments: Notwithstanding
the requirements of paragraphs 4.1 and 4.2, Biogen Idec shall not be obligated
to make either the sales-based milestone payment of paragraph 4.1 or the future
royalty payments of paragraph 4.2 under any of the following circumstances,
provided, however, that any payment made under paragraphs 4.1 and 4.2 prior to
such circumstances shall be non-refundable and non-creditable:

                  4.3.1 Biogen Idec shall not be obligated to make any such
payments for any time period after which (a) all of the ASSERTED CLAIMS have
expired or have been declared invalid or unenforceable by a final judgment or
decree in an action brought by or against a THIRD PARTY, that is not further
reviewable because of settlement, exhaustion of all permissible applications for
rehearing or review by a superior tribunal, or expiration of the time permitted
for such applications (such claims being "INVALID"); and (b) there is no other
issued United States patents from THE KAMINSKI PATENT FAMILY with at least one
claim that is not INVALID and that, except for this AGREEMENT, would be
infringed (including contributorily or by inducement ) by the making, use, sale
or offer for sale of the ZEVALIN KITS. Furthermore, if there is any time period
where U.S. Patent No. 6,565,827 is the only patent from THE KAMINSKI PATENT
FAMILY with valid and enforceable claims, Biogen Idec also shall not be
obligated to pay either the sales-based milestone payment of paragraph 4.1 or
the future royalty payments of paragraph 4.2 on the sales of any ZEVALIN KITS
which are covered by the '827 COVENANT NOT TO SUE.

                  4.3.2 Biogen Idec shall not be obligated to make any such
payments if a [*] in the [*] of the ZEVALIN KITS, or in the [*] of the [*]
thereof, or in the [*] for which the ZEVALIN KITS are [*], means that the
making, using, selling, offering for sale, or importing of the ZEVALIN KITS
would not, in the absence of the license granted herein or any other license to
THE KAMINSKI PATENT FAMILY, infringe (including contributorily or by inducement)
any claim of any then issued patent of THE KAMINSKI PATENT FAMILY that has not
been determined to be INVALID. Biogen Idec hereby acknowledges that the ZEVALIN
KITS as currently formulated and approved for sale in the United States are
subject to this royalty provision under the ASSERTED CLAIMS of THE KAMINSKI
PATENT FAMILY as currently in effect.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       8

<PAGE>

                  4.3.3 If Biogen Idec believes that any of the royalty payment
exceptions identified in paragraphs 4.3.1 or 4.3.2 is applicable, it shall
provide Corixa with written notice of such belief and the basis thereof and
identify the sales that it believes are subject to such exception (provided,
however, that no sales prior to the date notice is delivered pursuant to this
paragraph 4.3.3 shall be subject to such exception) (the "EXCEPTION SALES"). The
PARTIES agree to resolve any dispute about these issues through the dispute
mechanism of paragraph 12. In pursuing any such dispute resolution with respect
to paragraphs 4.3.1 and 4.3.2 only, the only issue for determination in such
dispute resolution shall be whether the EXCEPTION SALES infringe the claims, as
properly construed, of any then issued patents of THE KAMINSKI PATENT FAMILY
that have not been separately determined to be INVALID and which are not subject
of the `827 COVENANT NOT TO SUE. In pursuing any such dispute resolution with
respect to paragraphs 4.3.1 and 4.3.2 only, the [*] the [*] of certain [*]
appearing in the [*] (the "[*]") shall be [*] with respect to the [*] of: (1)
the ASSERTED CLAIMS; and (2) the [*] appearing in the non-ASSERTED CLAIMS of the
`721, `542, `365 and `537 Patents. However, this [*] shall not be binding on the
[*] of such claims if such claims have been [*] or are the subject of further
[*] (such as a [*] or [*]), and shall not be [*] on the claim [*] of the claims
of any other patent of THE KAMINSKI PATENT FAMILY. A determination that
EXCEPTION SALES are not royalty-bearing shall not affect the royalty-bearing
nature of any other sales of ZEVALIN KITS that are properly the subject of the
royalty provisions hereunder.

                  4.3.4 If disputed by Corixa, Biogen Idec will pay Corixa
royalties on the EXCEPTION SALES until it has obtained either the written
consent of Corixa to terminate such payments or a final determination (a
judgment that is not further reviewable because of settlement, exhaustion of all
permissible applications for rehearing or review by a superior tribunal, or
expiration of the time permitted for such applications) that such EXCEPTION
SALES are subject to either the paragraph 4.3.1 or 4.3.2 royalty payment
exception. Any and all royalty payments made on EXCEPTION SALES which sales
occurred after the written notice required by 4.3.3 are refundable as long as
Biogen Idec, within six (6) months of the written notice, files a lawsuit or
initiates an alternative mutually-agreed-upon dispute resolution mechanism to
resolve the issue of whether the royalty payment exception of paragraph 4.3.1
and/or 4.3.2 is applicable. Alternatively, If Biogen Idec does not file a
lawsuit or alternative dispute resolution mechanism within six (6) months of the
written notice, then only those royalty payments made on EXCEPTION SALES which
occurred after the filing of the lawsuit or alternative dispute resolution
mechanism are refundable. If it is determined by agreement or through final
determination that some or all of the EXCEPTION SALES were subject to either the
paragraph 4.3.1 or 4.3.2 royalty payment exception, then, within forty-five (45)
days of such determination or agreement, Corixa will refund to Biogen Idec any
and all such refundable royalties paid on those EXCEPTION SALES plus interest at
the rate of two percent (2%) over prime rate of interest as published in the
Federal Reserve Bulletin H.15 or a successor bulletin thereto calculated from
the date of receipt by Corixa. Interest shall be compounded annually, on each
January 1. GSK will be [*] Corixa for the payment to Biogen IDEC of this refund
plus interest.

            4.4 Sales by AFFILIATES and ZEVALIN SUBLICENSEES: If Biogen Idec
authorizes any AFFILIATE or ZEVALIN SUBLICENSEE to sell ZEVALIN KITS or any part
thereof that creates a royalty obligation under this AGREEMENT, such agreement
shall include an obligation for such AFFILIATE or ZEVALIN SUBLICENSEE to account
for and report its

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       9

<PAGE>

NET SALES of ZEVALIN KITS in the same manner as if such sales had been made by
Biogen Idec, and Biogen Idec shall pay royalties to Corixa as if the sales of
such AFFILIATE or ZEVALIN SUBLICENSEE had been sales of Biogen Idec.

            4.5 Reports: As to any CALENDAR YEAR from 2004 through [*], Biogen
Idec shall within forty-five (45) days of the end of such CALENDAR YEAR furnish
Corixa a written report of NET SALES of ZEVALIN KITS in the United States during
such preceding CALENDAR YEAR (except that such report for the first [*] days of
the year [*] shall be due [*]). Such report shall include the determination of
NET SALES, setting forth the quantity of units sold and otherwise distributed,
amount of gross receipts and deductions taken from gross receipts to arrive at
NET SALES and the determination of royalty owed on NET SALES. Concurrently with
each report, Biogen Idec shall make the royalty payment then due to Corixa.
Payments shall be in U.S. dollars, and, unless, otherwise agreed in writing,
shall be made by wire transfer of immediately available funds to such account of
Corixa as Corixa may from time to time designate in writing. If no royalties are
due, the report shall so state.

            4.6 Audits: Biogen Idec shall keep, and shall exercise commercially
reasonable efforts to cause those AFFILIATES and ZEVALIN SUBLICENSEES identified
in paragraph 4.4 to keep, true, complete and accurate records of all sales of
ZEVALIN KITS upon which royalties are due in accordance with GAAP, and in
sufficient detail to confirm the accuracy of Biogen Idec's royalty calculations.
At Corixa's request and expense, Biogen Idec shall permit, no more than once in
a twelve month period, an independent certified public accountant, appointed by
Corixa and acceptable to Biogen Idec, to examine, at Biogen Idec's principal
place of business, upon reasonable notice and at reasonable times, the records
of Biogen Idec and such records as Biogen Idec collects from those AFFILIATES
and ZEVALIN SUBLICENSEES identified in paragraph 4.4, solely to the extent
necessary to verify the royalty calculations; provided that Biogen Idec may
require such accountant to enter into a customary confidentiality agreement.
Biogen Idec shall be responsible for providing access to such records that in
the ordinary course of business are in the possession or control of those
AFFILIATES and ZEVALIN SUBLICENSEES identified in paragraph 4.4. Such
examination shall be limited to a period of time no more than three (3) years
immediately preceding the request for examination. The report of any such
examination shall be made simultaneously to Corixa and Biogen Idec and shall
simply report the amount, if any, by which Biogen Idec has overpaid or underpaid
its royalties. If Biogen Idec's royalties are found to be in error such that
royalties to Corixa were underpaid, then Biogen Idec shall promptly pay the
deficiency plus interest at the rate of two percent (2%) over prime rate of
interest as published in the Federal Reserve Bulletin H.15 or a successor
bulletin thereto, from time to time (with interest to be compounded annually, on
each January 1); and if royalties to Corixa were underpaid by more than five
percent (5.0%), then Biogen Idec shall additionally reimburse Corixa for its
reasonable out-of-pocket costs incurred in examining such records. In the event
that an audit determines that Biogen Idec has overpaid royalties to Corixa for
one or more audited CALENDAR YEARS, Biogen Idec shall be entitled to credit any
such overpayment against royalties payable in the next CALENDAR YEAR. Corixa
shall treat all financial information subject to review under this Section 4.6
as confidential, and shall cause its accounting firm to treat all such financial
information in confidence. Biogen Idec shall contractually obligate each ZEVALIN
SUBLICENSEE identified in paragraph 4.4 to agree to maintain records sufficient
to audit the calculation of NET SALES by such sublicensee, and to permit audits
in accordance with this paragraph 4.6.

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       10

<PAGE>

            4.7 Dispute Over Payments Under Paragraphs 4.1 And 4.2: In the event
that Corixa, Coulter, Michigan and GSK believe that Biogen Idec has not complied
with its obligations under paragraphs 4.1 or 4.2, they shall provide Biogen Idec
with written notice thereof. This written notice shall provide an explanation of
the nature of the alleged lack of compliance and the actions believed to be
necessary to cure such lack of compliance. Biogen Idec shall have forty-five
(45) days from receipt of such written notice to comply with such notice or to
provide written notice that it disputes the allegation that it is not in
compliance with paragraph 4.1 or 4.2. If Biogen Idec provides written notice
that it disputes the allegation that it is not in compliance with paragraph 4.1
or 4.2, then the PARTIES will have a thirty-day time period to negotiate in good
faith the dispute and attempt to reach a resolution thereof. If the PARTIES are
unable to reach resolution, then the PARTIES shall submit the dispute to a
mediator for non-binding resolution according to the provisions of paragraph 12.

      5. WARRANTIES:

            5.1 Corixa, Coulter, Michigan and GSK warrant that: (i) they [*]
have a [*] interest in THE KAMINSKI PATENT FAMILY and THE WAHL PATENT FAMILY to
grant the licenses set forth in paragraph 3.1 above (including, without
limitation, such that [*] from [*] an [*] in any [*] of THE KAMINSKI PATENT
FAMILY or THE WAHL PATENT FAMILY will be [*] by Biogen Idec, or any assignee or
sublicensee of Biogen Idec hereunder, under THE KAMINSKI PATENT FAMILY or THE
WAHL PATENT FAMILY [*] [*]); and (ii) they have the right to grant the licenses,
with right to sublicense, described in such paragraph 3.1.

            5.2 Biogen Idec warrants that: (i) it has a [*] interest in THE
NEORX PATENT FAMILY to grant the licenses set forth in paragraph 3.2 above
(including, without limitation, such [*] from [*] an [*] in any [*] of THE NEORX
PATENT FAMILY will be [*] for Corixa, Coulter and GSK, or any assignee or
sublicensee of Corixa, Coulter or GSK hereunder, under THE NEORX PATENT FAMILY
[*]); and (ii) it has the right to grant the licenses, with right to sublicense,
described in such paragraph 3.2.

            5.3 The PARTIES hereby warrant to each other that they have not
sold, assigned, transferred, conveyed or otherwise disposed of any claim or
other right or interest inconsistent with this AGREEMENT.

            5.4 Each PARTY shall indemnify and hold the other PARTY(IES), its
AFFILIATES and its and their SUBLICENSEES, harmless against any and all claims,
demands, actions, proceedings, liabilities, losses, damages, costs, and
expenses, including, without limitation, reasonable expert witness and
attorneys' fees and costs arising from or related to any suit or claim by a
THIRD PARTY which is based upon a breach of the representations and warranties
made by the representing PARTY in sections 5.1 to 5.3 above.

      6. NO CHALLENGES TO EACH OTHER'S LICENSED PATENTS:

            6.1 NO CHALLENGES RE KAMINSKI PATENT FAMILY AND WAHL PATENT FAMILY

                  6.1.1 Coulter, Corixa, GSK and Michigan hereby each agree that
neither it nor any AFFILIATE or any licensee or sublicensee of THE KAMINSKI
PATENT FAMILY

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       11

<PAGE>

or WAHL PATENT FAMILY will file or prosecute, or encourage or assist directly or
indirectly any THIRD PARTY in filing or prosecuting, any claim, or lawsuit, or
claim, cross-claim or counterclaim for patent infringement of any of THE
KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY against the following persons or
entities: (a) any [*], [*] or [*] or facility to the extent it is a recipient of
ZEVALIN KITS for [*] and/or [*] to one or more [*]; (b) any [*] or [*] health
[*] to the extent it is a recipient of ZEVALIN KITS for [*] and/or [*] to one or
more [*]; (c) any [*], [*] or [*] health [*] to the extent [*] or [*] [*],
and/or [*] ZEVALIN to one or more [*]; (d) any health [*]; or (e) Biogen Idec,
its AFFILIATES and any SUBLICENSEES of the foregoing as well as any of their
distributors, importers, exporters, wholesalers, manufacturers and customers.
Subpart (e) of this paragraph 6.1.1 shall be null and void and of no further
force or effect solely with respect to any of Biogen Idec, its AFFILIATES or any
of its SUBLICENSEES that breach any provisions of this Section 6.

                  6.1.2 Biogen Idec agrees that neither it nor any AFFILIATE
will initiate or prosecute, or encourage or assist directly or indirectly any
THIRD PARTY in initiating or prosecuting, any claim, or lawsuit, or claim,
cross-claim or counterclaim in any lawsuit, or any administrative proceeding
(including without limitation any proceeding with the United States Patent and
Trademark Office or its counterpart agency in any other country) challenging the
validity, inventorship or enforceability of THE KAMINSKI PATENT FAMILY and WAHL
PATENT FAMILY, except as required by law (e.g., such as responding to subpoena
for documents or testimony). As to THE KAMINSKI PATENT FAMILY and THE WAHL
PATENT FAMILY, Biogen Idec, its AFFILIATES, and any SUBLICENSEE hereunder (but
solely for the duration of their sublicense, as provided in paragraph 6.1.3),
waive any and all invalidity, inventorship and unenforceability defenses in any
future litigation, arbitration, or other legal or administrative proceeding;
provided, however, that nothing in this paragraph prevents Biogen Idec or its
AFFILIATES or its SUBLICENSEES from:

                           (i) challenging the validity, enforceability,
      inventorship or scope of [*] of U.S. Patent No. [*] and any [*] in THE
      KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY as of the [*] of this [*] in
      the context of Biogen Idec or its AFFILIATES or its SUBLICENSEES', as
      applicable, [*] or [*] (including but not limited to, the [*] of any [*]
      including those [*] in the [*] and [*] and [*] under [*] and [*], [*], or
      [*] for [*] relating thereto) any intellectual property rights that the
      applicable entity owns or controls (other than THE KAMINSKI PATENT FAMILY
      and WAHL PATENT FAMILY), except that in the context of any [*], Biogen
      Idec, its AFFILIATES and, subject to paragraph 6.1.3, its SUBLICENSEES
      expressly waive the right to raise, assert, use or rely on any [*] that
      [*] the [*] of this Agreement;

                           (ii) [*] any and all [*] [*] to Biogen Idec, its
      AFFILIATES and its SUBLICENSEES in any [*] or [*] by a THIRD PARTY [*]
      them, including, without limitation, [*] relating to the [*], [*], [*] or
      [*] of any patent in THE KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY;
      and

                           (iii) [*] any and all [*] to Biogen Idec, its
      AFFILIATES and its SUBLICENSEES in any [*] them or their SUBLICENSEES,
      [*], or [*] for [*] of any patent of THE KAMINSKI PATENT FAMILY or WAHL
      PATENT FAMILY,

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       12

<PAGE>

      including, without limitation, [*] relating to the [*] or [*] of any
      patent in THE KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY.

                  6.1.3 Biogen Idec agrees that, if it grants any sublicense to
THE KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY as permitted under paragraph
3.1.3 of this AGREEMENT, such sublicense will include an obligation on the part
of the intended sublicensee to be bound by paragraph 6.1.2 for the duration of
such sublicense, provided however, that such intended sublicensee may have the
right to terminate the sublicense and thereafter be no longer bound by paragraph
6.1.2.

                  6.1.4 Corixa, Coulter, Michigan and GSK each agree that, if it
grants any sublicense to THE KAMINSKI PATENT FAMILY and WAHL PATENT FAMILY after
the EFFECTIVE DATE of this AGREEMENT, such sublicense will include an obligation
on the part of such intended SUBLICENSEE to be bound by paragraph 6.1.1 for the
duration of such sublicense.

            6.2 NO CHALLENGES RE NEORX PATENT FAMILY

                  6.2.1 Biogen Idec hereby agrees that neither it nor any
AFFILIATE or any licensee or sublicensee of THE NEORX PATENT FAMILY will file or
prosecute, or encourage or assist directly or indirectly any THIRD PARTY in
filing or prosecuting, any claim, or lawsuit, or claim, cross-claim or
counterclaim for patent infringement of any of THE NEORX PATENT FAMILY against
the following persons or entities: (a) any [*], [*] or [*] or facility to the
extent it is a recipient of BEXXAR for [*] and/or [*] to one or more [*]; (b)
any [*] or [*] health [*] to the extent it is a recipient of BEXXAR for [*]
and/or [*] to one or more [*]; (c) any [*], [*] or [*] health [*] to the extent
[*] or [*], and/or [*] BEXXAR to one or more [*]; (d) any health [*]; and (e)
Corixa, Coulter, GSK, their AFFILIATES and any SUBLICENSEES of the foregoing as
well as any of their distributors, importers, exporters, wholesalers,
manufacturers, or customers. Subpart (e) of this paragraph 6.2.1 shall be null
and void and of no further force or effect solely with respect to any of Corixa,
Coulter, GSK, their AFFILIATES or any of their SUBLICENSEES that breach any
provisions of this Section 6.

                  6.2.2 Corixa, Coulter, and GSK each agree that neither they
nor any AFFILIATE will initiate or prosecute, or encourage or assist directly or
indirectly any THIRD PARTY in initiating or prosecuting, any claim, or lawsuit,
or claim, cross-claim or counterclaim in any lawsuit, or any administrative
proceeding (including without limitation any proceeding with the United States
Patent and Trademark Office or its counterpart agency in any other country)
challenging the validity, inventorship or enforceability of THE NEORX PATENT
FAMILY, except as required by law (e.g., such as responding to subpoena for
documents or testimony). As to THE NEORX PATENT FAMILY, Corixa, Coulter and GSK,
its AFFILIATES, and any SUBLICENSEE hereunder (but solely for the duration of
their sublicense, as provided in paragraph 6.2.3), waive any and all invalidity,
inventorship and unenforceability defenses in any future litigation,
arbitration, or other legal or administrative proceeding; provided, however,
that nothing in this paragraph prevents Corixa, Coulter and GSK or their
AFFILIATES or SUBLICENSEES; and provided, however, that nothing in this
paragraph prevents Corixa, Coulter, and GSK or their AFFILIATES or SUBLICENSEES
from:

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       13

<PAGE>

                           (i) challenging the validity, enforceability,
      inventorship or scope of [*] in THE NEORX PATENT FAMILY in the context of
      Corixa, Coulter, and GSK or any of their AFFILIATES or their
      SUBLICENSEES's, as applicable, [*] or [*] (including but not limited to,
      the [*] of any [*] including those [*] in the [*] and [*] and [*] under
      [*] and [*], [*], or [*] for [*] relating thereto) any intellectual
      property rights that the applicable entity owns or controls (other than
      THE NEORX PATENT FAMILY), except that in the context of any [*], Corixa,
      Coulter and GSK, their AFFILIATES and, subject to paragraph 6.2.3, their
      SUBLICENSEES expressly waive the right to raise, assert, use or rely on
      any [*] that [*] the [*] of this Agreement;

                           (ii) [*] any and all [*] to Corixa, Coulter, and GSK
      and any of their AFFILIATES and SUBLICENSEES in any suit or [*] by a THIRD
      PARTY [*] them, including, without limitation, [*] relating to the [*],
      [*], [*] or [*] of any patent in THE NEORX PATENT FAMILY; and

                           (iii) [*] any and all [*] to Corixa, Coulter, and GSK
      and any of their AFFILIATES and SUBLICENSEES in any [*] them or their
      SUBLICENSEES, [*], or [*] for [*] of any patent of THE NEORX PATENT
      FAMILY, including, without limitation, [*] relating to the [*] or [*] of
      any patent in THE NEORX PATENT FAMILY.

                  6.2.3 Corixa, Coulter and GSK each agree that, if they grant
any sublicense to THE NEORX PATENT FAMILY as permitted under paragraph 3.2.3 of
this AGREEMENT, such sublicense will include an obligation on the part of the
intended sublicensee to be bound by paragraph 6.2.2 for the duration of such
sublicense, provided however, that such intended sublicensee may have the right
to terminate the sublicense and thereafter be no longer bound by paragraph
6.2.2.

                  6.2.4 Biogen Idec agrees that, if it grants any sublicense to
THE NEORX PATENT FAMILY after the EFFECTIVE DATE of this AGREEMENT, such
sublicense will include an obligation on the part of such intended sublicensee
to be bound by paragraph 6.2.1 for the duration of such sublicense.

      7. RELEASES:

            7.1 Corixa, Coulter, Michigan and GSK, for themselves and their
agents, successors, assigns, employees, representatives and attorneys, hereby
release and discharge Biogen Idec and its respective present or former officers,
directors, stockholders, employees, agents, AFFILIATES, partners, predecessors,
successors, heirs, executors, assigns and attorneys from any and all claims,
demands, actions, rights, causes of action, debts, obligations, costs, expenses,
attorneys' fees, damages, and liabilities of any kind or nature or character
whatsoever whether known or unknown, suspected or unsuspected, actual or
potential, absolute or contingent, pending or anticipated, which relate to any
and all allegations or claims of infringement of any patents of THE KAMINSKI
PATENT FAMILY and THE WAHL PATENT FAMILY with respect to any acts committed
prior to the EFFECTIVE DATE of this AGREEMENT, any and all claims that were or
could have been made in THE LAWSUITS, any and all claims which arise out of or
are connected to any occurrence or conduct alleged or

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       14

<PAGE>

referred in THE LAWSUITS which occurred prior to the EFFECTIVE DATE of this
AGREEMENT, and any and all claims which arise out of or are connected to the
filing, prosecution, and defense of THE LAWSUITS.

            7.2 Biogen Idec, for itself and its agents, successors, assigns,
employees, representatives and attorneys, hereby releases and discharges Corixa,
Coulter, Michigan and GSK and their respective present or former officers,
directors, stockholders, employees, agents, AFFILIATES, partners, predecessors,
successors, heirs, executors, assigns and attorneys from any and all claims,
demands, actions, rights, causes of action, debts, obligations, costs, expenses,
attorneys' fees, damages, and liabilities of any kind or nature or character
whatsoever whether known or unknown, suspected or unsuspected, actual or
potential, absolute or contingent, pending or anticipated, which relate to any
and all allegations and claims of infringement of any patents of THE NEORX
PATENT FAMILY with respect to any acts committed prior to the EFFECTIVE DATE of
this AGREEMENT, any and all claims that were or could have been made in THE
LAWSUITS, any and all claims which arise out of or are connected to any
occurrence or conduct alleged or referred in THE LAWSUITS which occurred prior
to the EFFECTIVE DATE of this AGREEMENT, and any and all claims which arise out
of or are connected to the filing, prosecution, and defense of THE LAWSUITS.

            7.3 It is specifically understood that this AGREEMENT may be pleaded
as a full and complete defense to, and may be used as a basis for an injunction
against any action, suit, or other proceeding, which may be instituted,
prosecuted, or attempted in breach of this AGREEMENT.

      8. WAIVER OF CIVIL CODE 1542: The PARTIES specifically understand,
acknowledge and agree that this is a full and final release, applying to any and
all of the claims released in paragraphs 7.1 and 7.2 , whether known or unknown.
The PARTIES, having been fully advised by their respective counsel, hereby
expressly waive the benefit of the provisions of Section 1542 of the Civil Code
of the State of California, which provides as follows, and under all federal,
state and common-law statutes or principles of similar effect:

                  A general release does not extend to claims which the creditor
            does not know or suspect to exist in his favor at the time of
            executing the release, which if known by him must have materially
            affected his settlement with the debtor.

      9. NO OTHER LICENSES:

            9.1 The licenses granted hereunder are limited to those patent
families specifically identified. Nothing in this AGREEMENT or the course of
dealings between the PARTIES or usage or custom in the industry or trade shall
be construed to confer any other rights or licenses to any other patents by
implication, estoppel or otherwise.

            9.2 Without limitation of the foregoing, this AGREEMENT does not
grant any license under any patents (including U.S. Patent No. [*]) issuing from
the application for United States Letter Patent Serial No. [*], filed [*], for
the invention titled "[*]."

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       15

<PAGE>

            9.3 Furthermore, Biogen IDEC agrees that it has released and shall
never assert any claim or defense of an implied license under any theory or
course of dealing, including under [*] agreement between [*] and [*], to any of
the patents in THE KAMINSKI PATENT FAMILY in connection with any patents
(including U.S. Patent No. [*]) issuing from the application for [*], filed [*],
for the invention titled "[*]."

      10. ASSIGNMENTS OF RIGHTS:

            10.1 Biogen Idec may not assign or transfer its rights and
obligations under this AGREEMENT to a non-AFFILIATE that does not purchase
substantially all of Biogen Idec's rights associated with ZEVALIN(R) without
each of Corixa, Coulter, Michigan and GSK's consent, which shall not be
unreasonably withheld. The failure to respond in writing to a written request
for consent within 30 days shall be deemed to be consent. Each of Corixa,
Coulter, Michigan and GSK may not assign or transfer its rights and obligations
under this AGREEMENT to a non-AFFILIATE that does not purchase substantially all
of their rights associated with BEXXAR(R) without Biogen Idec's consent, which
shall not be unreasonably withheld. The failure to respond in writing to a
written request for consent within 30 days shall be deemed to be consent. Such
assignments or transfers shall include in writing terms and conditions
sufficient to obligate such assignee or transferee to comply with the assignor's
obligations under this AGREEMENT. In all instances, the following obligations
shall remain binding upon the initial PARTIES notwithstanding any assignment or
transfer: paragraphs 1, 5.4, 6, 7, 8, 9, 12, 14 and 15. Except as provided
otherwise in this paragraph, in the event of any assignment or transfer, the
assignor's obligations will be passed on to the assignee without further
recourse to the assignor.

            10.2 Biogen Idec may assign or otherwise transfer part or all of the
rights, title or interest to THE NEORX PATENT FAMILY, provided that any such
assignment or transfer includes terms and conditions sufficient to obligate any
such assignee or transferee to comply with Biogen Idec's obligations under this
AGREEMENT with respect to THE NEORX PATENT FAMILY, including, without
limitation, (i) an acknowledgement of the licenses granted under paragraph 3.2
above and (ii) agreement to the covenant not to sue set forth in paragraph 6.2.1
above.

            10.3 Biogen Idec may assign or otherwise transfer part or all of the
rights, title or interest to the ZEVALIN KITS, provided that any such assignment
or transfer includes terms and conditions sufficient to obligate any such
assignee or transferee to comply with Biogen Idec's obligations under this
AGREEMENT with respect to the ZEVALIN KITS, including, without limitation,
agreement to make the reports and to pay the amounts set forth in paragraph 4
above.

            10.4 Biogen Idec may assign or transfer its rights and obligations
under this AGREEMENT to an AFFILIATE that does not purchase substantially all of
Biogen Idec's rights associated with ZEVALIN(R), provided that Biogen Idec
remains responsible for the performance by the assignee of its obligations under
this AGREEMENT.

            10.5 Coulter, Corixa, Michigan and GSK may assign or otherwise
transfer part or all of the rights, title or interest to THE KAMINSKI PATENT
FAMILY and THE WAHL

                                               *CONFIDENTIAL TREATMENT REQUESTED

                                       16

<PAGE>

PATENT FAMILY, Provided That Any Such Assignment Or Transfer Includes Terms And
Conditions Sufficient To Obligate Any Such Assignee Or Transferee To Comply With
The Obligations Of Coulter, Corixa, Michigan And Gsk Under This AGREEMENT With
Respect To THE KAMINSKI PATENT FAMILY And THE WAHL PATENT FAMILY, including,
without limitation, (i) an acknowledgement of the licenses granted under
paragraph 3.1 above and (ii) agreement to the covenant set not to sue forth in
paragraphs 6.1.1 above.

      11. TERM: This AGREEMENT shall come into force as of the EFFECTIVE DATE
and shall continue in full force and effect, until the expiration of the last to
expire of any of THE KAMINSKI PATENT FAMILY, WAHL PATENT FAMILY or NEORX PATENT
FAMILY, except that paragraphs 4 and 12 of this AGREEMENT, and all other
provisions necessary to interpret and give effect to paragraph 4, shall remain
in full force and effect until all milestone payments and royalties that accrued
under paragraph 4 prior to the expiration of such patents have been paid and any
related disputes have been resolved, and except that the confidentiality
provisions of paragraph 15 shall remain in full force and effect without
expiration.

      12. AGREEMENT TO MEDIATE DISPUTES OR CLAIMS ARISING FROM AGREEMENT: If a
dispute arises out of or relates to this AGREEMENT, or the breach thereof, the
Parties agree to first attempt to resolve the dispute through negotiation. If
the dispute cannot be settled through negotiation, the PARTIES agree to next try
in good faith to settle the dispute by mediation before resorting to
arbitration, litigation, or some other dispute resolution procedure.
Notwithstanding this paragraph 12, any PARTY may commence and pursue litigation
or administrative remedies with respect to disputes arising out of or relating
to this AGREEMENT (i) ninety (90) days following an initial written notice of
such dispute to the other PARTIES or (ii) at any time, in the event that a PARTY
files in a court of competent jurisdiction a motion for temporary restraining
order, preliminary injunction or similar equitable relief which solely involve
paragraphs 6 or 15 of this AGREEMENT.

      13. NOTICES: Any notice, request, approval or other document required or
permitted to be given under this AGREEMENT shall be in written and shall be
delivered by an overnight courier service (such as Federal Express) or by
certified or registered mail, return receipt requested, addressed as follows, or
to such other address or fax number as the PARTY may have subsequently
designated by written notice to all other PARTIES:

                                       17

<PAGE>

            13.1  If to Biogen Idec:

                  Biogen Idec Inc.
                  14 Cambridge Center
                  Cambridge, MA 02142
                  Attention: General Counsel
                  Fax No.: 617-679-2838

            13.2  If to Corixa or Coulter:

                  Corixa Corporation
                  1124 Columbia Street, Suite 200
                  Seattle WA 98104
                  Attention: General Counsel
                  Fax No.: 206-754-5994
                  Coulter Corporation
                  c/o Corixa Corporation
                  [At the same address and fax number as above]

            13.3  If to Michigan:

                  Director of Licensing
                  Attention: File 1009
                  University of Michigan
                  Office of Technology Transfer
                  2071 Wolverine Tower
                  3003 S. State Street
                  Ann Arbor, MI 48109-1280
                  Fax No.: 734-936-1330

            13.4  If to GSK:

                  SmithKline Beecham Corporation,
                  doing business as GlaxoSmithKline
                  Corporate Law Department
                  One Franklin Plaza
                  20 N. 16th Street
                  Philadelphia, PA 19006
                  Attention: Senior Vice President & General Counsel
                  Fax No.: 610-270-5713

      14. COSTS AND FEES: Each PARTY shall bear its own costs, attorneys' fees
and other expenses, incurred in connection with THE LAWSUITS and this AGREEMENT.

      15. CONFIDENTIALITY:

            15.1 This AGREEMENT, and all its terms, shall be maintained in
confidence by the PARTIES, provided that any PARTY may make such disclosures
required by law,

                                       18

<PAGE>

including financial or corporate reporting obligations. Notwithstanding the
foregoing, each PARTY may state the existence and amount of the upfront payment
in their financial reports, and may state that THE LAWSUITS between the PARTIES
have settled with the payment by Biogen Idec of an upfront settlement payment, a
sales-based milestone payment, and a royalty payment on United States sales of
ZEVALIN(R) KITS. Each PARTY may disclose, and provide copies of, this AGREEMENT
and its terms to AFFILIATES and financial, accounting, tax and securities law
advisors, who shall each agree to identical nondisclosure obligations as set
forth in this section 15. Furthermore, notwithstanding the foregoing, a PARTY
may disclose the terms of this Agreement to an actual or potential AFFILIATE,
SUBLICENSEE or a potential acquirer of a PARTY or certain of its assets
including those subject to this AGREEMENT, as reasonably necessary to the
conduct of the PARTY's business, provided that such disclosure is accompanied by
an agreement obligating the party receiving the information to keep the
information confidential. Michigan may disclose the financial terms of this
AGREEMENT to its inventors of THE KAMINSKI PATENT FAMILY, who shall each agree
in writing to identical nondisclosure obligations as set forth in this paragraph
15.

            15.2 In the event that a PARTY is served with a legal document
demanding the production or disclosure of this AGREEMENT or the terms or
provisions of this AGREEMENT, such Party shall give notice of the same to the
other PARTIES as soon as practicable and in any event shall not produce or
disclose the terms of this AGREEMENT until the other PARTIES have received
notice and have had an opportunity to oppose the demand if appropriate. In the
event that a PARTY is advised in good faith by legal counsel that disclosure of
any of the terms or provisions of this AGREEMENT is required pursuant to the
reporting requirements of any law (including but not limited to the reporting
requirements of the Securities Exchange Commission or related law or regulations
or comparable laws or regulations in a foreign country), then such PARTY shall
provide notice of the intended public disclosure (including the precise language
of the disclosure) to the other undersigned PARTIES at least 48 hours before
making such disclosure. The Protective Order entered in the Lawsuits shall
survive dismissal and be complied with by the PARTIES per its terms.

      16. SUCCESSORS: This AGREEMENT shall inure to the benefit of and be
binding upon the PARTIES' respective successors and assigns.

      17. COUNTERPARTS: This AGREEMENT may be executed in several counterparts,
and shall be effective when so executed by all PARTIES identified below and
thereupon shall constitute one agreement, binding on all PARTIES hereto,
notwithstanding that all PARTIES are not signatory to the original or the same
counterpart.

      18. FINAL EXPRESSION OF AGREEMENT: Except for the `827 COVENANT NOT TO SUE
and the Settlement and License Agreement entered into between SmithKline Beecham
Corporation and Idec Pharmaceuticals Corporation dated November 14, 2002, this
AGREEMENT and all associated papers represent and contain the entire agreements
among the PARTIES with respect to the subject matter of this AGREEMENT, and
supersedes any and all prior or contemporaneous oral and written negotiations,
agreements and understandings, including the Memorandum of Agreement dated
February 27, 2004. No representation, warranty, condition, understanding or
agreement of any kind with respect to the subject matter hereof shall be relied
upon by the PARTIES except those expressly contained herein. This

                                       19

<PAGE>

AGREEMENT may not be amended or modified or waived except as agreed in writing
by all PARTIES.

      19. PORTION VOID: Should any word, clause, phrase, or portion of this
AGREEMENT be judicially declared to be to any extent void or unenforceable, such
portion shall be construed as if it were written so as to effectuate, to the
maximum extent possible and enforceable, the PARTIES' intent, and in any event
such portion shall be considered independent and severable from the remainder of
the AGREEMENT, the validity of which shall remain unaffected.

      20. DRAFTED BY THE PARTIES: In the event of a dispute, this AGREEMENT
shall be interpreted in accordance with its fair meaning and shall not be
interpreted for or against any PARTY hereto on the ground that such PARTY
drafted or caused to be drafted this AGREEMENT or any part thereof. Accordingly,
the PARTIES agree that the normal rule of construction to the effect that any
ambiguities are to be resolved against the drafting PARTY shall not be employed
in the interpretation of this AGREEMENT.

      21. GOVERNING LAW: This AGREEMENT is made pursuant to, and shall be
governed by, the internal laws of the State of California. The PARTIES agree
that this AGREEMENT shall be enforceable in any court of competent jurisdiction
within the State of California.

      22. ADVICE OF COUNSEL: The PARTIES hereto acknowledge that they have each
consulted, conferred with, and obtained the advice of their respective legal
counsel, prior to executing this AGREEMENT; that they have entered into and
executed this AGREEMENT voluntarily and with full knowledge and appreciation of
the meaning, scope, effect and significance of each and every provision
contained herein; and that they do not rely and have not relied upon any
representation or statement made by any other PARTY or any of their
representatives or attorneys with regard to the subject matter, consideration,
scope, basis or effect and significance of this AGREEMENT.

      23. NO ADMISSION OF LIABILITY: It is understood and agreed that this
AGREEMENT is a compromise of disputed claims and that the offer and acceptance
of consideration by the PARTIES is not to be construed as admission of liability
by any PARTY, which liability is expressly denied.

      24. KNOWING AND VOLUNTARY EXECUTION: The PARTIES hereto, and each of them,
further represent and declare that they have carefully read this AGREEMENT and
know the contents thereof and that they sign the same freely and voluntarily.

                                       20

<PAGE>

      IN WITNESS WHEREOF the PARTIES have executed this AGREEMENT on the dates
indicated below. The signatories below represent that they have the authority to
sign for the entity for which they sign and that their signature is binding upon
that entity.

BIOGEN IDEC INC.                        CORIXA CORPORATION

By: /s/ William R. Rohn                 By: /s/ Kathleen McKereghan
    ------------------------                ----------------------------

Its: Chief Operating Officer            Its: Sr. VP, General Counsel & Secretary

Dated: May 7, 2004                      Dated: May 7, 2004

COULTER PHARMACEUTICAL INC.             SMITHKLINE BEECHAM CORPORATION,
                                        d/b/a GlaxoSmithKline

By: /s/ Kathleen McKereghan             By: /s/ Ronald Parman
      ----------------------                ----------------------------

Its: Secretary                          Its: Vice President and Secretary

Dated: May 7, 2004                      Dated: May 7, 2004

REGENTS OF THE UNIVERSITY OF
MICHIGAN

By: /s/ Kenneth J. Nisbet
    ------------------------
Its: Executive Director, UM
     Technology Transfer

Dated: May 6, 2004

                                       21<PAGE>

                                                                    EXHIBIT 10.1

                                             * CONFIDENTIAL TREATMENT HAS BEEN
                                             REQUESTED FOR THE MARKED PORTIONS
                                             OF THIS EXHIBIT PURSUANT TO RULE
                                             24B-2 OF THE SECURITIES EXCHANGE
                                             ACT OF 1934, AS AMENDED.

                                                  July 20, 2004

SmithKline Beecham plc
New Horizons Court
TW8 9EP
United Kingdom
Attn :  Jean Stephenne

RE:   LETTER AMENDMENT TO MPL AGREEMENTS

Dear Jean:

      This letter amendment (this "Amendment") memorializes our understanding
and agreement to amend the MPL Agreements regarding the scale-up of the
production of 3-O-deacylated monophosphoryl lipid A from Salmonella minnesota
R595 ("MPL") and the manufacture and supply of MPL by Corixa Corporation
("Corixa") to SmithKline Beecham plc ("GSK").

   1. INTRODUCTION

      By merger with Ribi ImmunoChem, Inc. ("Ribi"), Corixa is party to the
following agreements with GSK or one of its affiliates:

      (a)   License and Supply Agreement, dated May 3, 1991, between Ribi and
            SmithKline Beecham Biologicals, S.A. ("SBBio") (the "1991
            Agreement");

      (b)   License/Supply Agreement, entered into December 10, 1992, between
            Ribi and GSK (the "1992 Agreement");

      (c)   License/Supply Agreement, dated December 1, 1995, between Ribi and
            SBBio (the "1995 Agreement");

      (d)   License and Supply Agreement, dated December 31, 1996, between Ribi
            and SmithKline Beecham Biologicals Manufacturing s.a., as amended by
            Letter Agreement dated December 12, 2001 (the "1996 Agreement"); and

      (e)   License/Supply Agreement, entered into October 5, 1999, between Ribi
            and GSK (the "1999 Agreement").

      The foregoing five (5) agreements are referred to herein collectively as
      the "MPL License and Supply Agreements".

      In addition, Corixa is party to the following agreements with affiliates
      of GSK:

<PAGE>

      (f)   Letter Agreement, dated December 5, 2000, between Corixa and SBBio
            (the "2000 Agreement"); and

      (g)   MPL Fermentation/Purification Collaboration Agreement, dated
            December 2, 2002, between Corixa and GlaxoSmithKline Biologicals,
            S.A. (the "2002 Agreement").

      The foregoing two (2) agreements together with the MPL License and Supply
      Agreements are referred to herein collectively as the "MPL Agreements".

   2. DEFINITIONS

      (a)   "1991 Agreement", "1992 Agreement", "1995 Agreement", "1996
            Agreement", "1999 Agreement", "2000 Agreement" and "2002 Agreement"
            shall have the respective meanings ascribed to them in Section 1 of
            this Amendment.

      (b)   "CSC" shall have the meaning ascribed to it in Section 3 (b) (i) of
            this Amendment.

      (c)   "Evaluation" shall have the meaning ascribed to it in Section 3 (a)
            (i) of this Amendment.

      (d)   "Exercise Fee" shall have the meaning ascribed to it in Section 3
            (d) (ii) of this Amendment.

      (e)   "Facility Modifications" shall have the meaning ascribed to it in
            Section 3 (a) (iii) of this Amendment.

      (f)   "FDA" shall have the meaning ascribed to it in Section 3 (a) (i) of
            this Amendment.

      (g)   "Force Majeure" shall have the meaning ascribed to it in the 1996
            Agreement.

      (h)   "Hamilton Facility" shall have the meaning ascribed to it in Section
            3 (a) of this Amendment.

      (i)   "Know-How" shall have the meaning ascribed to it in the MPL License
            and Supply Agreements.

      (j)   "Manufacturing Know-How" shall mean all present and future technical
            information and know-how owned and/or controlled by Corixa with the
            right to grant licenses during the term of this Amendment or the
            co-exclusive license referred to in Section 3 (d) below, which is
            useful or necessary to produce (a) MPL, (b) intermediates used in a
            process required or useful for manufacturing MPL, (c) improvements
            of MPL or (d) intermediates used in a process required or useful for
            manufacturing improvements of MPL, and which technical information
            and know-how shall include, without limitation, any and all process,
            manufacturing, control, assay, QC, and any other information
            relating to MPL and/or manufacture of MPL and all documentation and
            technical assistance needed or useful for the production of Product.

                                                                               2

<PAGE>

      (k)   "Manufacturing Patents" shall mean all patents and patent
            applications owned and/or controlled by Corixa with the right to
            grant licenses during the term of this Amendment or the co-exclusive
            license referred to in Section 3 (d) below, which patents and patent
            applications claim a process required or useful for manufacturing
            (a) MPL, (b) intermediates used in a process required or useful for
            manufacturing MPL, (c) improvements of MPL or (d) intermediates used
            in a process required or useful for manufacturing improvements of
            MPL. Included within the definition of Manufacturing Patents are any
            continuations, continuations-in-part, divisions, patents of
            addition, reissues, renewals or extensions of the patents and patent
            applications described in the foregoing sentence. The current list
            of Manufacturing Patents is set forth in Exhibit I attached hereto.

      (l)   "MPL" shall have the meaning ascribed to it in the first paragraph
            of this Amendment.

      (m)   "MPL Agreements" shall have the meaning ascribed to it in Section 1
            of this Amendment.

      (n)   "MPL License and Supply Agreements" shall have the meaning ascribed
            to it in Section 1 of this Amendment.

      (o)   "Net Sales" shall have the meaning ascribed to Net Invoice Price or
            Net Sales in the MPL License and Supply Agreement applicable to the
            sold Product.

      (p)   "Option" shall have the meaning ascribed to it in Section 3 (d) (i)
            of this Amendment.

      (q)   "Option Period" shall have the meaning ascribed to it in Section 3
            (d) (ii) of this Amendment.

      (r)   "Patents" shall have the meaning given thereto in the MPL License
            and Supply Agreements. The current list of Patents is attached
            hereto as Exhibit II.

      (s)   "Product" shall have the meaning ascribed to it in the MPL License
            and Supply Agreements.

      (t)   "Report" shall have the meaning ascribed to it in Section 3 (a) (ii)
            of this Amendment.

      (u)   "Transfer Request Period" shall have the meaning ascribed to it in
            Section 3 (e) (ii) of this Amendment.

      (v)   "Work Plan" shall have the meaning ascribed to it in Section 3 (b)
            (i) of this Amendment.

   3. TERMS OF AMENDMENT

      (a)   Evaluation of Corixa's Hamilton, MT MPL Manufacturing Facility (the
            "Hamilton Facility").

                                                                               3

<PAGE>

            (i)   The parties hereby agree that Corixa shall engage [*] of [*]
                  as a consultant for the evaluation of the Hamilton Facility
                  for licensability to produce MPL bulk drug substance,
                  according to current United States Food and Drug
                  Administration ("FDA") regulations and guidelines (the
                  "Evaluation").

            (ii)  The [*] all costs related to the Evaluation, up to a maximum
                  of USD[*], with [*] responsible for a maximum of [*]. Any
                  costs related to the Evaluation above USD[*] shall be [*].
                  Both parties shall have access to [*] written report resulting
                  from the Evaluation ("Report").

            (iii) In the event the Evaluation determines that the Hamilton
                  Facility is licensable for the production of MPL bulk drug
                  substance, according to current FDA regulations and
                  guidelines, or upon Corixa warranting in writing to GSK that
                  [*] it will promptly implement the modifications defined in
                  writing during the Evaluation and recorded in the Report as
                  necessary for the Hamilton Facility to be so licensable ("the
                  Facility Modifications"), and further warranting to make any
                  further necessary modifications that may from time to time be
                  required in order to maintain the Hamilton Facility in
                  compliance at all times with FDA and European Union regulatory
                  authorities regulations and guidelines, then the parties shall
                  proceed in accordance with the terms and conditions set forth
                  in Sections 3 (b) through 3 (f) below.

      (b)   Scale-Up of MPL Production

            (i)   Promptly after issuance of the Report and in parallel with
                  making the Facility Modifications, if any, Corixa shall
                  initiate the efforts described in Stage I and Stage II of the
                  work plan attached hereto as Exhibit IIIA, which is
                  incorporated herein by this reference (the "Work Plan"), as
                  may be amended from time to time by written agreement of the
                  parties. The parties shall establish a Collaboration Steering
                  Committee (the "CSC") in accordance with Exhibit IIIB, which
                  Exhibit is incorporated herein by this reference, to oversee
                  the performance of the Work Plan. Corixa shall keep GSK
                  apprised in writing of the progress accomplished in
                  implementing the Facility Modifications and in performing the
                  Work Plan through quarterly written progress reports to GSK.
                  FTE Costs associated with progress report generation are
                  included in the Work Plan.

            (ii)  GSK shall fund fifty percent (50%) of all of Corixa's FTEs
                  costs involved in performing the Work Plan for Stage I and
                  Stage II, which funding shall be payable quarterly in advance
                  based upon Corixa's invoice therefore and receipt of Corixa
                  written report for activities performed during the preceding
                  quarter. Corixa shall be obligated to dedicate all of such
                  funding received from GSK to the performance of the Work Plan.
                  If such report(s) show that Corixa is not executing the Work
                  Plan, GSK shall have the right to withhold such funding,
                  provided, however, that GSK's license under

                                                                               4

                                               *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                  Section 3 (d) (i) shall not include any Manufacturing Patents
                  or Manufacturing Know-How developed during any period that GSK
                  does not fund fifty percent (50%) of all of Corixa's FTEs
                  costs for such period. The FTE rate applicable to the Work
                  Plan shall be Corixa's 2004 FTE rate of USD$[*], increased
                  annually by COLA. Neither Corixa nor GSK shall have an
                  obligation to contribute to FTE costs exceeding those outlined
                  specifically in Exhibit IIIA. Corixa shall be [*] incurred as
                  part of the Work Plan. Any modification to the Work Plan must
                  be agreed to in writing between the two parties. Any savings
                  or additional expense to be incurred as a result of Work Plan
                  modification shall be shared equally between the two parties.

            (iii) The Work Plan shall supersede the work plan attached as
                  Exhibit A to the 2002 Agreement and the parties agree and
                  acknowledge that no further efforts shall be required of
                  either party pursuant to such Exhibit A.

            (iv)  Any process improvement and/or MPL improvement made, conceived
                  and reduced to practice as part of the Work Plan solely by
                  Corixa or GSK or made, conceived and reduced to practice
                  jointly by Corixa and GSK will be co-owned by Corixa and GSK,
                  who will each have co-exclusive (as used herein,
                  "co-exclusive" shall have the meaning provided in Section 3
                  (d) (i) hereof) rights to use such improvement(s) for any
                  purpose unless otherwise expressly provided in this Amendment.
                  No consideration other than that specified in this Amendment
                  shall be due by either party to the other for use of such
                  improvement(s). Any patent application claiming such
                  improvement(s) will be filed in the joint names of Corixa and
                  GSK. For the avoidance of doubt, any modification of MPL
                  fermentation, extraction, purification, characterization or
                  analytical processes that is made, conceived or reduced to
                  practice as a result of experimentation carried out under the
                  Work Plan or outside of the Work Plan but jointly by or on
                  behalf of Corixa or its employees and by or on behalf of GSK
                  or its employees, including by or on behalf of GSK or its
                  employees with input from Corixa or its employees, whether at
                  laboratory bench-scale or pilot plant scale manufacturing but,
                  if made, conceived or reduced to practice by or on behalf of
                  GSK other than jointly with Corixa, in no event later than the
                  date the CSC determines the Work Plan to be completed or
                  terminated, shall be deemed to have been made, conceived and
                  reduced to practice, as applicable, as part of the Work Plan
                  and shall be co-owned and co-exclusively licensed by Corixa
                  and GSK as described above.

                  Subject to Section 3 (d) (ii) following successful completion
                  of the Work Plan such that Corixa is able to produce at least
                  1.8 kg of MPL per year and that the terms of Section 3 (c) (v)
                  hereof apply, any process improvement and/or MPL improvement
                  made, conceived and reduced to practice solely by GSK or
                  Corixa thereafter shall be solely owned by the party that
                  made,

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                               5

<PAGE>

                  conceived and reduced to practice such improvement subject to
                  the following:

                  (x) Any such improvements made, conceived and reduced to
                  practice solely by Corixa before expiration of GSK royalty
                  obligation pursuant to Section 3 (d) (iii) (a) shall be part
                  of MPL Know-How or MPL Patents.

                  (y) Any such improvements made, conceived and reduced to
                  practice solely by Corixa after expiration of GSK royalty
                  obligation pursuant to Section 3 (d) (iii) (a) shall not be
                  part of MPL Know-How or MPL Patents provided, however that if
                  GSK so requests in writing, Corixa and GSK shall negotiate in
                  good faith commercially reasonable terms for a license from
                  Corixa for GSK to use such improvement(s) in the manufacture
                  by GSK of MPL for use as a prophylactic and/or therapeutic
                  vaccine adjuvant.

                  (z) Without prejudice to Section 3 (d) (ii) below, GSK shall
                  have exclusive rights to such improvements which are solely
                  owned by it and no obligation to provide a license to such
                  improvements to Corixa.

            (v)   In addition to the performance of the Work Plan and only after
            GSK has paid the Exercise Fee pursuant to Section 3 (d) (ii), GSK
            shall have the right to perform MPL process development work on its
            own and/or to sub-contract to third parties MPL process development
            work and shall be the sole owner of any developments resulting from
            such work; provided that any such subcontractor(s) shall be subject
            to nondisclosure and nonuse restrictions, at least as stringent as
            those applicable to GSK as set forth in the MPL License and Supply
            Agreements, in respect of all Manufacturing Know-How and any other
            know-how related to the manufacture of MPL.

            (vi)  Corixa and GSK agree that the Patent Committee set-up under
            the Multi-Field Vaccine Discovery Collaboration and License
            Agreement, effective September 1, 1998, between Corixa and GSK, as
            amended, will oversee the prosecution of any patents resulting from
            the Work Plan and the 2002 Agreement. For purposes of clarification,
            if GSK exercises its Option it will have co-exclusive rights to
            manufacture MPL under any patent claiming any Inventions under the
            2002 Agreement.

      (c)   Long-Term MPL Supply

            (i)   GSK shall order from Corixa guaranteed minimum annual orders
                  of MPL to be delivered in quarterly amounts by Corixa in
                  accordance with the following schedule:

                  2004 = [*]
                  2005 = [*] ([*] each quarter)
                  2006 = [*] ([*] each quarter)

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                               6

<PAGE>

                  2007 = [*] ([*] each quarter)
                  2008 = through 2012 = 1.8 kgs per year (450 grams each
                  quarter)

                  and under the terms of the Quality Agreement attached hereto
                  as Exhibit IV, which is incorporated herein by this reference,

                  provided, however, that:

                  (x) if, in any calendar quarter, Corixa supplies GSK with at
                  least [*] percent ([*]%) of the quantity to be delivered
                  during that quarter according to the schedule above and Corixa
                  supplies GSK with the full annual guaranteed minimum order of
                  MPL to be delivered according to the schedule above during
                  that calendar year, GSK shall not invoke Corixa's failure to
                  supply under Section 3 (c) (iii) below.

                  (y) if the Facilities Modifications, if any, are not complete
                  by [*] for any reason other than Force Majeure, GSK shall be
                  entitled to apply a [*] percent ([*]%) reduction to the price
                  set forth in Section 3 (c) (iv) for MPL produced and accepted
                  by GSK during the time period beginning [*] and ending upon
                  completion of the Facilities Modifications, and to the
                  applicable royalty due, if any, under the MPL Supply and
                  License Agreements until [*] or the applicable royalty set
                  forth in Section 3 (d) (iii) (b) after [*], for the next
                  Product that will be sold by GSK during the time period
                  equivalent to the number of months beginning [*] and ending
                  upon completion of the Facilities Modifications; or

                  (z) if delivery to GSK of consistency lots of MPL which is
                  FDA-compliant after implementation of Stage I of the Work Plan
                  is not complete by [*] for any reason other than Force
                  Majeure, GSK shall be entitled to apply a [*] percent ([*]%)
                  reduction to the price set forth in Section 3 (c) (iv) for MPL
                  produced and accepted by GSK during the time period beginning
                  [*] and ending upon delivery to GSK of consistency lots of MPL
                  which is FDA-compliant, and to the applicable royalty due, if
                  any, under the MPL Supply and License Agreements until [*] or
                  the applicable royalty set forth in Section 3 (d) (iii) (b)
                  after [*], for the next Product that will be sold by GSK
                  during the time period equivalent to the number of months
                  beginning [*] and ending upon delivery to GSK of consistency
                  lots of MPL which is FDA-compliant.

                  Furthermore Corixa agrees to use commercially reasonable
                  efforts to complete the Facility Modifications and to deliver
                  the consistency lots by no later than [*] but in the event
                  that the Facilities Modifications are not completed by [*] for
                  any reason other than Force Majeure, or if the delivery of
                  consistency lots does not take place before [*] for any reason
                  other than Force Majeure, GSK may at its option upon written
                  notice to Corixa [*] and, if GSK has not yet exercised the
                  Option, [*] from Corixa for [*] as opposed to the [*] payment
                  called for in Section [*] or, if GSK

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                               7

<PAGE>

                  has previously exercised the Option, Corixa shall, at GSK's
                  option, [*] or provide [*] and any royalty due Corixa
                  thereafter hereunder [*].

                  The MPL supplied by Corixa shall meet the specifications set
                  forth in the Quality Agreement attached hereto as Exhibit IV
                  and all requirements of the FDA and European Union regulatory
                  authorities and shall be suitable for use in Products to be
                  sold in the United States and the European Union.

            (ii)  If GSK orders the minimum quantities above, GSK will be deemed
                  to have satisfied all its combined minimum transfer price and
                  royalty obligations under all MPL License and Supply
                  Agreements. Starting in 2006, upon request of GSK, Corixa
                  agrees that in the event it has the manufacturing capacity, it
                  shall make all reasonable commercial efforts to supply GSK
                  with quantities in excess of the quantities specified in
                  Section 3 (c) (i) above, up to a capacity of minimum 1.8 kg
                  per year in 2006 and 2007 and up to a capacity which exceeds
                  1.8 kg in 2008 and each year thereafter during the term of
                  this Amendment. GSK agrees to inform Corixa of any such
                  additional request at least twelve (12) months in advance.

            (iii) Corixa will use commercially reasonable efforts to supply GSK
                  with MPL ordered by GSK. Upon Corixa becoming aware of its
                  inability to supply MPL to GSK in accordance with the supply
                  schedule set forth in Section 3 (c) (i), Corixa shall promptly
                  notify GSK in writing of such inability and the date by which
                  Corixa reasonably anticipates being able to supply in
                  accordance with such schedule. Except as set forth in Section
                  3 (c) (vi) or if the failure to supply is due to Force
                  Majeure, if Corixa is unable to supply in accordance with such
                  schedule for more than [*] days but less than [*] and [*]
                  days, then the royalty due by GSK to Corixa hereunder shall be
                  reduced by [*] on sales of that number of Products that GSK
                  otherwise would have sold but for the fact that Corixa was
                  unable to supply the amount of MPL required for such Product
                  sale(s), as calculated in accordance with the following
                  example. If in a given year, Corixa was unable to supply
                  product for [*] days, the amount of the annual production
                  missed will be deemed to be [*] of that year's production [*]
                  days [*] days). If the contracted amount to be purchased by
                  GSK in that year was [*], the amount of MPL associated with
                  Corixa's failure to supply would be calculated as [*] of [*]
                  or [*]. Assuming that there are [*] of MPL per dose of Product
                  (or that [*] is the [*] amount of MPL per dose of Product if
                  there are different Products with different amounts of MPL),
                  GSK would be entitled to reduce the royalty owed to Corixa by
                  [*] on [*] doses of Product (calculated as [*]). Such royalty
                  reduction shall apply to the first [*] doses of Product sold
                  by GSK. However, if once Corixa returns to production, Corixa
                  is able to become current with the supply schedule in terms of
                  total material shipped to GSK, then royalties due Corixa on
                  sales of further Products shall be as specified in
                  3(d)(iii)(b).

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                               8

<PAGE>

                  Except as set forth in Section 3 (c) (vi) or if the failure to
                  supply is due to Force Majeure, if Corixa is unable to supply
                  in accordance with such schedule for more than [*] and [*] but
                  less than [*] and [*], then the royalty due by GSK to Corixa
                  hereunder shall be reduced by [*] on sales of that number of
                  Product that GSK otherwise would have sold but for the fact
                  that Corixa was unable to supply the amount of MPL required
                  for such Product sales(s), as calculated in accordance with
                  the following example. If in a given year, Corixa was unable
                  to supply product for [*] days, the amount of the annual
                  production missed will be deemed to be [*] of that year's
                  production [*] days [*]. If the contracted amount to be
                  purchased by GSK in that year was [*], the amount of MPL
                  associated with Corixa's failure to supply would be calculated
                  as [*] of [*], or [*]. Assuming that there are [*] of MPL per
                  dose of Product (or that [*] is the [*] amount of MPL per dose
                  of Product if there are different Products with different
                  amounts of MPL), GSK would be entitled to reduce the royalty
                  owed to Corixa by [*] on [*] doses of Product (calculated as
                  [*]. Such royalty reduction shall apply to the first [*] doses
                  of Product sold by GSK. However, if once Corixa returns to
                  production, Corixa is able to become current with the supply
                  schedule in terms of total material shipped to GSK, then
                  royalties due Corixa on sales of further Products shall be as
                  specified in 3(d)(iii)(b).

                  Except as set forth in Section 3 (c) (vi) or if the failure to
                  supply is due to Force Majeure, if Corixa is unable to supply
                  in accordance with such schedule for more than [*] and [*]
                  days, GSK shall have the right to terminate the supply
                  provisions of this Amendment and the MPL License and Supply
                  Agreements for breach of Corixa and: (x) there will be no [*]
                  Corixa [*] on sales of that number of Products that GSK
                  otherwise would have sold but for the fact that Corixa was
                  unable to supply the amount of MPL required for such Product
                  sales(s), as calculated in accordance with the following
                  example. If in a given [*] year period, Corixa was unable to
                  supply product for [*] days, the amount of the production
                  missed will be deemed to be [*] of that year plus the prior
                  [*] production [*] days [*] days. If the contracted amount to
                  be purchased by GSK in that year plus the prior [*] was [*],
                  the amount of MPL associated with Corixa's failure to supply
                  would be calculated as [*] of [*], or [*]. Assuming that there
                  are [*] of MPL per dose of Product (or that [*] is the average
                  amount of MPL per dose of Product if there are different
                  Products with different amounts of MPL), GSK would be entitled
                  to pay [*] to Corixa on [*] doses of Product (calculated as
                  [*] x [*] grams). Such royalty reduction shall apply to the
                  first [*] doses of Product sold by GSK; and; (y) for the
                  subsequent sales the terms of Section 3(f)(ii) shall apply.

            (iv)  The pricing for all MPL ordered by GSK following the date of
                  this Amendment shall be USD[*] per gram, with an annual
                  increase based on COLA as reported by the United States Social
                  Security Administration.

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                               9

<PAGE>

            (v)   Notwithstanding the foregoing, if the Work Plan has been
                  successfully completed and in any calendar year following such
                  completion GSK orders more than 1.8 kg of MPL from Corixa, the
                  price in such year for such excess MPL shall be [*] of the
                  price set forth in Section 3 (c) (iv).

            (vi)  In the event the Hamilton Facility is shut down during 2005
                  due to process development activities required by the Work
                  Plan, GSK nonetheless shall pay Corixa in 2005 in four (4)
                  quarterly installments for the [*] of MPL that otherwise would
                  have been deliverable in 2005, provided that Corixa shall
                  deliver such [*] to GSK in 2006 in addition to the [*]
                  guaranteed annual minimum order for 2006 otherwise Corixa will
                  provide GSK with a credit of an amount prorated to the price
                  paid by GSK for the quantity not delivered.

            (vii) GSK shall be committed to purchase the quantities of MPL set
                  forth in Section 3 (c) (i) above through 2008. From 2009, GSK
                  shall have the right to cancel its guaranteed minimum annual
                  orders of MPL upon prior written notice of [*] to Corixa (e.g;
                  by no later than [*] in case GSK wishes to cancel its
                  guaranteed minimum annual orders of MPL for [*]) and payment
                  of the following cancellation fee to Corixa on the day of said
                  notification: for [*] a cancellation fee of USD$[*] [*]. In
                  addition, if GSK cancels its guaranteed minimum annual orders
                  of MPL according to this Section 3 (c) (vii), effective
                  immediately on the day of notification of such cancellation:
                  [*] and any further supply of MPL by Corixa at quantities
                  lower than those indicated in Section 3 (c) (i) above and/or
                  supply following the lapse of the [*] cancellation notice
                  period, will require a new supply agreement between GSK and
                  Corixa, (y) the royalty described in Section 3 (d) (iii) b.
                  shall be replaced by a flat royalty of [*]% ([*] percent) on
                  Net Sales of all Products for a Product-by-Product period of
                  [*] years post applicable Product introduction, (z) all MPL
                  license rights of GSK pursuant to the MPL License and Supply
                  Agreements [*] and GSK shall have [*] for any new vaccine
                  application and (xx) all MPL intellectual property, including
                  without limitation improvements and other know-how, developed
                  by or on behalf of GSK shall be promptly provided
                  free-of-charge to Corixa and Corixa shall have no obligation
                  to contribute any further MPL improvements to GSK.

            (d)   Co-Exclusive License to Manufacture MPL

            (i)   Subject to all terms and conditions of this Amendment, Corixa
                  hereby grants to GSK an option (the "Option") for a
                  co-exclusive, perpetual, non-sublicensable license under the
                  Manufacturing Patents and Manufacturing Know-How to
                  manufacture MPL (x) solely to meet any GSK annual requirements
                  after 2008 and through 2012 for MPL in excess of 1.8 kg and
                  after 2012 solely to meet GSK's requirements and (y) solely
                  for use in accordance with the applicable license grants set
                  forth below:

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              10

<PAGE>

<TABLE>
<CAPTION>
     AGREEMENT           APPLICABLE PROVISION(S)
------------------      -------------------------
<S>                     <C>
The 1991 Agreement      Sections 3.1 and 3.2

The 1992 Agreement      Section 3.1

The 1995 Agreement      Sections 3.1, 3.2 and 3.3

The 1996 Agreement      Sections 3.1, 3.4 and 3.5

The 1999 Agreement      Sections 3.1 and 3.2
</TABLE>

                  and for use in any other human vaccine application licensed to
                  GSK on a non-exclusive basis.

                  Co-exclusive license under this clause means that only Corixa
                  and GSK will be entitled to manufacture MPL for use as a
                  prophylactic and/or therapeutic vaccine adjuvant. No license
                  is hereby granted to GSK to manufacture MPL for any other
                  purpose. During the term of this co-exclusive license Corixa
                  shall promptly disclose to GSK and/or supply GSK with all
                  Manufacturing Know-How. Corixa shall retain exclusive rights
                  to manufacture MPL for any purpose other than use of MPL as a
                  prophylactic and/or therapeutic vaccine adjuvant. GSK and
                  Corixa shall each have the right to use subcontractors
                  (including Corixa, in the case of GSK) to make MPL for use as
                  a prophylactic and/or therapeutic vaccine adjuvant, provided
                  that such subcontractor(s) shall be subject to nondisclosure
                  and nonuse restrictions, at least as stringent as those
                  applicable to GSK and/or Corixa as set forth in the MPL
                  License and Supply Agreements, in respect of all Manufacturing
                  Know-How and any other know-how related to the manufacture of
                  MPL and provided that Corixa shall remain liable for all its
                  obligations hereunder. In the event GSK determines to engage a
                  subcontractor to manufacture MPL, GSK shall inform Corixa in
                  writing and Corixa shall have the right to make an offer for
                  the subcontract, provided that GSK shall have no obligation to
                  negotiate with Corixa. Nothing in this agreement shall be
                  interpreted as to prevent Corixa from transferring its MPL
                  manufacturing operations and business to a Corixa subsidiary
                  or any other Corixa affiliate provided that such affiliate or
                  subsidiary shall remain bound by all obligations, terms and
                  conditions applicable to Corixa under this Amendment. In the
                  event Corixa determines to dispose of its MPL manufacturing
                  operations and business, whether directly if held by Corixa or
                  by disposing of all or a majority ownership in any Corixa
                  affiliate or subsidiary to which it has transferred its MPL
                  manufacturing operations and business, Corixa shall inform GSK
                  in writing and GSK shall have the right to make an offer for
                  the available operations and business, or interest in such
                  affiliate or

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              11

<PAGE>

                  subsidiary, as applicable, provided that Corixa shall have no
                  obligation to negotiate with GSK.

            (ii)  After GSK has exercised the Option, any process improvement
                  and/or MPL improvement made, conceived and reduced to practice
                  by GSK other than jointly with Corixa which is not as part of
                  the Work Plan will be solely owned by GSK. Subject to the
                  provisions of Section 3 (c) (i) above, the Option shall be
                  exercised by GSK paying to Corixa USD$[*] (the "Exercise Fee")
                  in immediately available funds at any time during the period
                  commencing on the date of this Amendment and terminating
                  thirty (30) days following written notification by Corixa to
                  GSK that the CSC has determined that Corixa has completed the
                  Facility Modifications (the "Option Period"). In the event GSK
                  does not exercise the Option, this Amendment shall immediately
                  terminate and neither party shall have any further obligations
                  hereunder, provided that GSK shall not be relieved of any then
                  outstanding payment obligations pursuant to Section 3 (a)
                  (ii), pursuant to 3 (b) (ii) solely for any work performed as
                  of the date of termination under the Work Plan, or pursuant to
                  Section 3 (c) (iv) for any MPL produced by Corixa and
                  delivered to GSK hereunder as of the date of termination.

            (iii) Royalty.

                  a.    In consideration for the grant of the license hereunder
                        and other good and valuable consideration, GSK shall pay
                        Corixa a royalty on all Net Sales generated on or after
                        June 30, 2008, which royalty obligation shall expire for
                        all Products, ten (10) years after the first commercial
                        sale in the United States or Europe of GSK's Product for
                        the prevention and/or control and/or treatment of human
                        papilloma virus in humans or fifteen years (15) after
                        the first commercial sale in the United States or Europe
                        of GSK's Product for the prevention and/or control
                        and/or treatment of herpes simplex virus in humans if
                        GSK does not launch a Product for the prevention and/or
                        control and/or treatment of human papilloma virus in
                        humans, provided, however, that if the first commercial
                        sale of such Product occurs after June 30, 2008, GSK
                        shall continue to pay royalties in accordance with the
                        applicable MPL License and Supply Agreement on all Net
                        Sales of other Products until such first commercial
                        sale, after which only the royalty due under this
                        Amendment shall be payable on Net Sales.

                  b.    Royalties shall be payable on a Product-by-Product basis
                        according to the following schedule:

<TABLE>
<CAPTION>
Aggregate Annual Net Sales of
  the applicable Product                  Royalty
------------------------------            -------
<S>                                       <C>
   < or = USD$[*]                           [*]%

   > USD$[*] and < or =USD$[*]                   [*]%

        >USD$[*]                            [*]%
</TABLE>

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              12

<PAGE>

                        As an example, if a particular Product has aggregate
                        Annual Net Sales of USD$1 billion, the first USD$[*] of
                        such Net Sales shall bear a [*]% royalty, the next
                        USD[*] of such Net Sales shall bear a [*]% royalty and
                        the remaining USD$[*]n of such Net Sales shall bear a
                        [*]% royalty. If in the same year another Product has
                        aggregate annual Net Sales of USD$[*], all of such Net
                        Sales shall bear [*]% royalty.

                        The royalty rates under this Amendment shall not be
                        subject to reduction or offset for any reason.

                        During any period of time during which GSK will be
                        paying a royalty to Corixa under the applicable MPL
                        License and Supply Agreement(s) or, after June 30, 2008,
                        under this Amendment. Corixa shall not grant any rights
                        to MPL, nor supply MPL, to any third party for use as a
                        prophylactic and/or therapeutic vaccine adjuvant in
                        products exclusively licensed to GSK under the MPL
                        Supply and License Agreements.

            (e)   Technology Transfer

                  (i)   In the event GSK has exercised the Option in accordance
                        with Section 3 (d) (ii) of this Amendment, then, subject
                        to the terms and conditions of this Section 3 (e),
                        Corixa shall transfer to GSK on a co-exclusive basis all
                        Manufacturing Know-How for GSK's use solely in
                        connection with the practice of the license set forth in
                        Section 3 (d) (i).

                  (ii)  GSK shall have the right to request the foregoing
                        transfer of Manufacturing Know-How by providing written
                        notice to Corixa therefor during the period that
                        commences upon exercise of the Option and terminates on
                        the later of December 31, 2007 and the date the CSC
                        determines that the Work Plan is fully completed (the
                        "Transfer Request Period"). GSK shall have no right to a
                        transfer of the Manufacturing Know-How if GSK has not
                        provided Corixa a written request therefore during the
                        Transfer Request Period.

                  (iii) In the event GSK requests such transfer in writing in
                        accordance with Section 3 (e) (ii), the parties shall
                        negotiate in good faith a Manufacturing Know-How
                        transfer work plan, which work plan shall include the
                        FTE rate for Corixa's FTEs who will perform such work
                        plan and which work plan will be appended to this
                        Amendment as Exhibit V and thereupon shall be
                        incorporated into this Amendment.

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              13

<PAGE>

                  (iv)  Following agreement to the Manufacturing Know-How
                        transfer work plan, Corixa shall transfer to GSK all
                        then existing Manufacturing Know-How in accordance with
                        such work plan. GSK shall fund Corixa's efforts in
                        performing such work plan as set forth therein, which
                        funding shall be payable quarterly in advance based upon
                        Corixa's invoice therefore.

            (f)   Term; Termination for Breach; No Termination for Convenience

                  (i)   GSK and Corixa hereby agree that after June 2008 the
                        licenses granted to GSK under all MPL License and Supply
                        Agreements will be fully-paid-up for any and all human
                        vaccine applications meaning that (x) subject to Section
                        3 (c) (vii), GSK shall have perpetual exclusive,
                        co-exclusive or non-exclusive licenses according to the
                        level of exclusivity under the current License and
                        Supply Agreements and non-exclusive license rights to
                        use MPL in any other human vaccine application, (y)
                        Corixa shall be entitled to supply MPL to a single third
                        party for use in Products for which GSK will have
                        co-exclusive licenses in perpetuity, shall be entitled
                        to supply MPL to third parties on a non-exclusive basis
                        for use in Products for which GSK will have
                        non-exclusive licenses in perpetuity and shall not be
                        entitled to supply MPL to any third party for use in
                        Products for which GSK will have exclusive rights in
                        perpetuity, and (z) GSK shall have no financial
                        obligation whatsoever to Corixa other than as
                        specifically provided under this Amendment and that GSK
                        shall be free to use MPL as an adjuvant in any and all
                        human vaccine applications, - provided, however, that if
                        the first commercial sale of GSK's Product for the
                        prevention and/or control and/or treatment of human
                        papilloma virus in humans occurs after June 30, 2008, or
                        in the case GSK does not launch a Product for the
                        prevention and/or control and/or treatment of human
                        papilloma virus in humans if the the first commercial
                        sale of GSK's Product for the prevention and/or control
                        and/or treatment of herpes simplex virus in humans
                        occurs after June 30, 2008, GSK shall continue to pay
                        royalties in accordance with the applicable MPL License
                        and Supply Agreement on all Net Sales of other Products
                        until such first commercial sale. GSK and Corixa further
                        acknowledge and agree that the terms of this Amendment,
                        including but not limited to the obligation of GSK to
                        pay a royalty in accordance with Section 3 (d) (iii)
                        above, incorporate the negotiated terms of continued
                        supply of MPL by Corixa to GSK after June 2008. GSK and
                        Corixa further acknowledge and agree that after the
                        expiration of the royalty obligation under Section 3 (d)
                        (iii) above, GSK's license under Section 3 (d) (i) above
                        shall be fully paid-up for any and all human vaccine
                        applications.

                        Unless extended as provided for herein, this Amendment
                        shall terminate on December 31, 2012. GSK shall have the
                        right to extend the term of this Amendment for
                        successive period(s) of three (3) years by providing
                        Corixa (a) thirty-six months written notice(s) of
                        extension. GSK's guaranteed annual minimum order of MPL
                        during each year of such

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              14

<PAGE>

                        extension, if applicable, shall be 1.8 kg unless
                        otherwise mutually agreed to by the parties.

                  (ii)  Each party shall have the right to terminate this
                        Amendment based on the other party's material breach,
                        which termination shall be effective ninety (90) days
                        following written notice of such breach to the breaching
                        party, provided that this Amendment shall not terminate
                        if the breaching party cures such breach within such
                        ninety (90) day period.

                  (iii) Except as set forth in Section 3 (c) (vi) or if the
                        failure to supply is due to Force Majeure, in case
                        Corixa is unable to supply GSK minimum annual orders as
                        specified in Section 3 (c) (i) for more than [*] and [*]
                        days, GSK shall have the right upon written notice to
                        Corixa to terminate the supply provisions of this
                        Amendment and the MPL License and Supply Agreements and
                        there will be no [*] Corixa [*] on sales of that number
                        of Products that GSK otherwise would have sold but for
                        the fact that Corixa was unable to supply the amount of
                        MPL required for such Product sales(s), as calculated in
                        accordance with the example set forth in subsection (x)
                        of the third paragraph of Section 3 (c) (iii), and for
                        subsequent sales, GSK's obligation to pay royalties to
                        Corixa shall continue in accordance with Section 3 (d)
                        (iii) (b), provided, however, that such royalties on all
                        subsequent sales of Product by GSK shall be reduced to
                        [*] of the rates set forth in Section 3 (d) (iii) (b).
                        If GSK has not exercised its Option at the time GSK
                        terminates the supply provisions under this Amendment
                        and the MPL License and Supply Agreement, there will be
                        no [*] Corixa on sales of any Product after such
                        termination.

                  (iv)  Except if the failure to meet the applicable due date is
                        due to Force Majeure, if Corixa does not complete the
                        Facilities Modifications or does not deliver to GSK
                        consistency lots of FDA-compliant MPL by [*] as further
                        described in Section 3 (c) (i), then the terms and
                        conditions of Section 3 (c) (i) related to exercise of
                        the Option and the Exercise Fee shall apply and if GSK
                        has exercised the Option, GSK shall have the right upon
                        written notice to Corixa to terminate the supply
                        provisions of this Amendment and the MPL License and
                        Supply Agreements and the royalties on all subsequent
                        sales of Product by GSK shall be reduced by [*] of the
                        rates set forth in Section 3 (d) (iii) (b).

                  (v)   In the event of either of the foregoing terminations of
                        the supply provisions of this Amendment and the MPL
                        License and Supply Agreements described in Sections 3
                        (f) (iii) and (iv), Corixa shall immediately transfer
                        all [*] to GSK and GSK shall thereafter have no further
                        financial obligations whatsoever to Corixa under this
                        Amendment or any of the MPL License and Supply
                        Agreements other than payment of the royalties called
                        for in this Section 3(f)(ii) and funding FTE costs to
                        effect the Manufacturing Know-How transfer under Section
                        3 (e) (iv) above.

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              15

<PAGE>

                  (vi)  No Termination for Convenience. The following provisions
                        of the MPL License and Supply Agreements are hereby
                        deleted in their entirety:

<TABLE>
<CAPTION>
     AGREEMENT              APPLICABLE PROVISION(S)
------------------          -----------------------
<S>                         <C>
The 1991 Agreement                Section 7.3

The 1992 Agreement                Section 7.3

The 1995 Agreement                Section 14.6

The 1996 Agreement                Section 7.3

The 1999 Agreement                Section 14.6
</TABLE>

      (g)   Fulfillment and Termination of 2000 Agreement; Repayment of Credit
            Line

            (i)   Fulfillment and Termination of 2000 Agreement. Corixa shall
                  deliver to GSK three (3) lots of MPL, with each lot being [*]
                  to [*] of MPL prepared using bacterial [*] master seed [*].
                  GSK shall pay to Corixa USD$[*] per gram for each such lot.
                  Corixa shall have no further obligation to supply to GSK and
                  GSK shall have no further obligation to purchase from Corixa,
                  any MPL pursuant to the 2000 Agreement and the 2000 Agreement
                  is hereby terminated and of no further force or effect,
                  provided, however, that Paragraph 2 thereof shall survive this
                  termination and provided further that GSK shall have no
                  further obligation under Section 4.7 of the 1991 Agreement.

            (ii)  Repayment of Credit Line. When Corixa has implemented all
                  Facility Modifications and has warranted in writing to GSK
                  that it will make all other necessary investments to upgrade
                  the Hamilton Facility as necessary to produce GSK's
                  requirements of MPL in accordance with regulations and
                  guidelines of regulatory authorities in the United States and
                  the European Union, Corixa shall be entitled to repay the
                  credit line described in Section 6 (b) (C) of the Multi-Field
                  Vaccine Discovery Collaboration and License Agreement,
                  effective September 1, 1998, between Corixa and GSK, as
                  follows. Corixa shall issue to GSK that number of shares equal
                  to USD$5,000,000.00 divided by the average per share closing
                  price of Corixa Common Stock on the Nasdaq National Market as
                  reported in the Wall Street Journal for the thirty (30) day
                  trading period immediately preceding but not including the
                  date of this Amendment, and such issuance shall be payment in
                  full for such credit line. Following receipt of the Report
                  described in Section 3 (a) (ii), the parties shall negotiate
                  in good faith and agree upon a reasonable date by which the
                  Facilities

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              16

<PAGE>

                  Modifications, if any, should be implemented. In the event the
                  Facilities Modifications have not been completed by one
                  hundred and twenty (120) days following such agreed date, the
                  credit line shall not be repayable using Corixa common stock
                  and the USD$5,000,000.00 shall be due and payable in full
                  fifteen (15) days thereafter.

      (h)   Miscellaneous Terms

            (i)   Notices. All notices required or permitted to be given under
                  this Amendment or any of the MPL License and Supply Agreements
                  shall be addressed when to Corixa:

                  Corixa Corporation
                  1124 Columbia Street, Suite 200
                  Seattle, WA 98104
                  Attn: Chairman and Chief Executive Office

                  With a copy to: General Counsel

                  (ii)  Full Force and Effect. Except with respect to supply,
                        royalties and financial obligations and except as
                        amended or terminated hereby, the licenses under the MPL
                        License and Supply Agreements shall remain in full force
                        and effect in accordance with their respective terms and
                        conditions, which terms and conditions are hereby
                        incorporated by this reference. In the event of any
                        conflicts or inconsistencies between this Amendment and
                        the applicable MPL Agreement, this Amendment shall
                        prevail.

      [THIS SPACE LEFT INTENTIONALLY BLANK]

                                                                              17

<PAGE>

      By your execution of this Amendment as indicated below and delivery of a
signed counterpart to my attention, GSK shall agree to the terms and conditions
set forth above.

      Best regards.

      CORIXA CORPORATION

                  /s/ Steven Gillis
      -------------------------------------------
      By: Steven Gillis
      Its: Chairman and Chief Executive Officer

      AGREED TO AND ACCEPTED BY:

      SMITHKLINE BEECHAM PLC

           /s/ Jean Stephenne
      -------------------------------------------
      By: Jean Stephenne
      Its: Attorney-in-fact

                                                                              18

<PAGE>

                                    EXHIBIT I

                              MANUFACTURING PATENTS

<TABLE>
<CAPTION>
 CASE                          APPLICATION NUMBER            PATENT NUMBER
NUMBER      COUNTRY              FILING DATE                  FILING DATE         STATUS
------      -------            ------------------            ------------         ------
<S>         <C>                <C>                           <C>                  <C>
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
[*]
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
------      -------            ------------------            ------------         ------
</TABLE>

* [*] patent family included in both Exhibit I and II as the claims include [*]

                                                                              19

                                               *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                   EXHIBIT II

                                     PATENTS

<TABLE>
<CAPTION>
 CASE                      APPLICATION NUMBER         PATENT NUMBER
NUMBER      COUNTRY            FILING DATE             FILING DATE              STATUS
------      -------        -------------------        -------------             ------
<S>         <C>            <C>                        <C>                       <C>
[*]
</TABLE>

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              20

<PAGE>

                                  EXHIBIT IIIA

                                    WORK PLAN

1.0   INTRODUCTION

      [*] has [*] an [*]in their [*] for [*] per year by [*]. In order to [*]
      the [*] it will be [*] to address [*] in the [*], as well as [*]. These
      include [*] and a [*]. The program is divided into three stages, defined
      as follows [*] and [*] with current [*] to [*]

      [*] to develop an [*] and [*] which is [*]

      [*] and [*] the [*] into the [*] and [*] at the [*] may be [*] as early as
      [*].

2.0   SCOPE

The work plan described herein includes only Stages I and II. Stage III is not
included in the scope of this work plan.

A plan for Stage III will need to be developed separately if the parties
mutually agree to extend the scope of the work plan as to include Stage III. The
work plan for Stage I includes plans for [*] using the [*], and [*] that may
exist for this process [*].

For Stage II, the work plan [*] of a [*] of [*] of the [*] at [*] and [*]at [*].
The performance of [*] and costs and FTEs [*] with such [*] in the scope of this
work plan.

A Collaborative Steering Committee (CSC) will be formed for the purpose of [*]
to the [*] as required by the [*]. In addition, the committee shall represent
the respective companies for [*] and [*] as outlined in the Work Plan. Corixa
will issue written progress reports on a [*] that [*]of the Work Plan [*]. These
reports will be confidential information between GSK and Corixa.

3.0   GOALS/ASSUMPTIONS

MILESTONES (LISTED BELOW AND IN TABLE 1):

      Stage I

      [*] Complete [*] and [*] of [*].
      [*] Initiate [*] with [*]
      [*] Complete [*] with [*] and [*]

      Stage II

      [*] Complete [*] of [*] to [*]
      [*] Establish [*] for [*].
      [*] Complete [*] of [*] of [*] at [*].
      [*] Demonstrate [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              21

<PAGE>

TABLE 1. MILESTONES FOR STAGES I AND II OF THE WORK PLAN.

<TABLE>
<CAPTION>
 MILESTONE                         COMPLETION DATE     STATUS
-------------------------------------------------------------
<S>                                <C>                 <C>
Stage I

[*] and [*]                            [*]               [*]

Initiate [*] with [*].                 [*]               [*]

Complete [*] with [*]                  [*]               [*]

      Stage II

Complete [*] of [*] to [*].            [*]               [*]

Establish [*] for [*]                  [*]               [*]

Complete [*] of [*] of [*] at [*]      [*]               [*]

Demonstrate [*] at [*]                 [*]               [*]
</TABLE>

ASSUMPTIONS:

   1. GSK has [*] a [*] that [*] than [*] with the [*].

   2. Corixa will be able to able to optimize the [*] and/or [*] that result in
      [*] that has an [*] that is [*] to the [*] obtained with the [*].

   3. Corixa will have [*] FTES [*] to work on [*] in [*], and [*] FTEs in [*].
      This will require the [*] of [*] to the [*].

   4. The [*] will be a [*] that yields [*] of MPL(R) per year, when operated at
      full capacity.

Microsoft Project was used to develop project timelines and estimate required
FTE allocations. The Gantt chart, including Stages I through III, is attached to
this document as Figure 1. Assuming the [*] stated above, resource leveling was
applied to determine timing of tasks to avoid overallocation of resources.
Completion of Stage I was given highest priority. Tasks for Stage II were then
leveled to assume maximum use of [*] FTEs ([*] in year one). It may be possible
to reduce the times required for both Stages I and II to [*] by increasing the
number of [*] beyond the [*] currently required.

4.0   STAGE I [*]

One component of Stage I relates to [*] and [*] to [*]. The [*] steps are the
[*] for the current MPL(R) process. The proposed changes include [*] of a [*],
and [*] the [*] of the [*]. In the current process, lots of [*] are [*], such
that the amount of [*] a single [*] is approximately [*]. Therefore,
implementation of the proposed changes to the [*] will not [*] to the [*]. With
these changes the capacity of the [*] and [*] will [*] of the [*] of individual
[*]). Both [*] and [*] will be [*]. The maximum production capacity will
increase [*].

An additional component of Stage I will be to address any [*] for the current
process and facility. It is expected that the primary work effort for this
component will be [*] of a [*].

4.1   [*]

      The [*] in the current facility is designed to accommodate [*]. The work
      plan will be to [*] and [*] an [*] and [*]. The [*] may be [*] to the [*].
      Utilities [*] will have to be [*] of the [*] of the [*] and utility [*]
      will be [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              22

<PAGE>

                                              Estimated time and FTEs

            [*]

                  TOTAL: [*] FTE-YR

4.2   [*]

      Efforts will be applied to develop [*] and to qualify [*] and [*]:

         The method that is currently used for [*] the effect of [*] on the [*]
         and [*], as it involves [*] of [*] from the [*] and [*] of the [*],
         then analysis by [*]. In the analysis of [*] at both [*] results have
         [*] that [*] of the [*] have occurred prior to or during the analysis.
         It will be [*] to qualify the [*] for use in [*]. To avoid [*], an
         effort will be made to develop [*] that allow [*] of [*], in samples
         collected from the [*] and [*]. The [*] must be [*] to [*], and
         therefore [*] to [*]. Proposed [*].

         Additional [*] will need to be [*] and [*], so that the impact of [*]
         may be [*]. [*] will be established for both the [*] and [*]. These [*]
         will be applied to ensure that the [*] that is [*] to [*] by the [*].

      These efforts must be [*] to [*] of the [*].

      Estimated time and FTEs: [*]

4.3   [*]

      The [*] of [*] will need to be [*] by a [*] in [*] of the [*]. The [*]
      process is performed in a [*] vessel that is coupled with a [*]. The
      process consists of [*] of the [*] to [*]%[*] (to remove [*] with [*].
      Each of these steps is followed by [*] with the [*]. The maximum [*] in
      the [*]. Therefore, a [*] could almost be [*] by simply [*] all of the
      [*]. However, it will be desirable to [*] by [*] the [*] in the [*] (at
      least in part), thereby [*] the amount of [*] used in the [*] is used to
      [*]. In order to avoid increasing the [*], it will especially be desirable
      to [*] of the [*].

      The workplan for achieving a [*] of [*] will include [*] to develop the
      [*]. The focus of these [*] will be on [*] to increase the [*] during the
      [*] and [*], without sacrificing [*] (both [*] of [*] by [*] and [*]). The
      effect of [*] on [*] will first be examined at an [*], allowing a number
      of [*] to be [*]. This will be followed by performing [*] using a [*] of
      the [*]. The [*] will consist of a [*] attached to a [*], which model the
      [*] used in the [*]. Initial studies will be performed to [*] to the [*]
      developed with the [*] may then be [*] into the [*].

      Estimated time and FTEs: [*]

4.4   [*]

      [*] will be performed at [*] to [*] changes to the [*] that were developed
      at [*], and to allow [*] of the [*]. These [*] need only to be [*] through
      to the [*]. Analysis of the [*] will be performed to determine [*] with
      the [*] produced by the [*] and [*]). It is anticipated that this activity
      can occur during the [*] of the [*]. [*] will be revised to incorporate
      the [*].

      Estimated time and FTEs: [*]

4.5   [*]

      Following implementation of the [*] and [*] will be performed. The [*]
      will be used to confirm that the [*] to the [*], and that the [*] and [*]
      of the [*] obtained with the [*] are acceptable. For the [*], it may be
      sufficient to perform the process through to the [*]. However, appropriate
      [*] will need to have been developed to [*] and [*] for the [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              23

<PAGE>

      Estimated time and FTEs: [*]

4.6   [*]

      After implementation and validation of the [*] and [*] will be [*]. The
      first [*] made from a total of [*], will be [*] as [*]. The success of the
      [*] will be [*] based on [*] of both [*] and of [*]. The [*] FTEs assigned
      to this task are in addition to the [*] FTEs [*] for [*]. These additional
      FTES will be required for [*] that may be required for [*].

      Estimated time and FTEs: [*]

4.7   [*]

      In order to address [*] the [*] will need to be more [*]. The first step
      will be to review all [*] and identify the [*] will be performed to [*].
      These studies will serve to [*] the number of [*] that will be required. A
      [*] plan will then be [*], in which the [*] for each step are [*] and [*]
      are listed. This will be followed by [*] of [*] will be planned to
      minimize the [*] of [*] which must be [*]. Where possible, [*] will be
      used for the [*]. The FTE values below for the [*] are [*]. After
      completion of the [*] of [*], it will be possible to determine [*] of [*].

                                              Estimated time and FTEs:

      [*]

      TOTAL: [*] FTE-YR

4.8   DELIVERABLES - STAGE I

      The deliverables for Stage I are:
      [*] for studies performed at [*] to [*] for the [*].
      Successful completion of [*] with [*]
      Completion of [*] for the [*] and [*].
      Successful completion of [*] with added [*] and [*].
      Completion of [*] for [*].
      Improved [*] for [*] in [*] and [*]

4.9   RESOURCES - STAGE I

      The total FTE requirement for completion of Stage I is [*] FTE-YEARS,
      itemized as follows:

      [*]       FTE-yr

      [*]       FTE-yr

      [*]       FTE-yr

4.10  PRODUCTION OF MPL(R) DURING STAGE I

      The [*] of the [*] in the [*] will require a [*] of [*] of MPL(R) for a
      [*] of [*]. The impact of [*] on [*] needs to be [*]. Forecasted
      requirements by GSK are for [*] of MPL(R) in 2004,

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              24

<PAGE>

      and [*] in 2005. After [*] and [*] of the [*] the [*] will be [*] by [*].
      Following [*] will be [*], beginning with the [*] of [*] of MPL(R).

5.0   STAGE II [*]

Stage II of the project will involve [*] and [*] to [*] a [*]. Overall goals for
this work are as follows:

      Improve [*] of the [*].
          [*] with more [*].
          Develop [*] for [*].
          [*].
      Increase [*].
          Increase [*].
          Increase [*] of [*].
          Increase [*].
          Increase [*] of [*] and [*].
          Reduce [*], or [*] with [*].
     Reduce [*].
     Maintain [*] of [*] by [*].
     Complete [*] to demonstrate [*] of the [*].

For the [*] will be performed at [*] of up to [*]. However, at the [*], only a
[*] of the [*] will be [*] and [*], allowing [*] to be [*] at [*] of each of the
[*] will be [*]. This will allow [*] to be [*] using [*], and will [*] the
number of [*] that will be [*] at [*].

For most [*] may be [*] to be [*] to [*] by the [*], thereby providing some [*]
that [*] at [*] will [*]. However, it is expected that, prior to developing [*]
for the [*] process [*] it will be necessary to [*] is proposed to be [*] of the
[*]. The [*] will be used to [*] and [*] for [*], and to develop [*] for [*]
equipment.

5.1   [*]

      [*] has developed a [*] that [*] and an [*] that is similar to [*] with
      the [*] of the new [*] has been [*] and will be completed during the [*].
      In order to complete the [*], Corixa will need to [*], and will need to
      perform [*] that show [*] to [*] at Corixa will be [*] using [*].
      Following [*], Corixa will continue to [*] to provide [*] for [*], to
      further [*] the [*] to achieve the required [*], and to demonstrate [*].
      FTE estimates for this work includes [*] of the [*] to determine [*] and
      establish [*].

                                              Estimated time and FTEs

      [*]

      TOTAL: [*] FTE-YR

5.2   [*]

      During [*] and [*] remain [*] of the [*] occurs, resulting in an increase
      in [*]. It will be necessary to develop [*] that result in [*] that is [*]
      to that [*] by the [*]. The preferred approach may be to [*] the [*] so
      that [*] in [*] is [*].

      Since [*] at time of [*] is [*] on the [*] of the [*] will need to be
      completed before development of the [*] can be [*]. First, [*] will be
      performed to [*] of [*] and [*]. Next, [*] will be tested and further [*]
      using a [*]. The [*] will be used to [*] and to [*] for the [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              25

<PAGE>

      Alternative technologies for [*], such as [*], will be considered for the
      [*]. The alternative options [*] will be assessed for [*], ability to [*]
      and [*] to determined the [*] for the [*]. Assessment of [*] may require
      [*] at [*] (FTE and cost [*].

                                              Estimated time and FTEs

      [*]

      TOTAL: [*] FTE-YR

5.3   [*]

      Tasks related to the [*] may be categorized as primary and secondary
      objectives, as follows.

      Primary Objectives

      1.    Develop [*]: The work plan will include [*] focused on developing
            conditions to further [*] the [*] during the [*] and [*], without
            [*] (both [*] of [*] and [*] of [*]). This will result in [*] of [*]
            during this step. The effect of [*] on [*] will first be examined at
            an [*], allowing a number of [*] to be [*] in [*]. This will be
            followed by [*] using a [*] of the [*]. The [*] consists of a [*]
            and [*], which serves as a [*] of the [*] and [*] used in the [*].
            The [*] will be used to develop the [*] for the [*] will be required
            prior to [*] for the [*].

      2.    [*]. It may be possible to [*] the process conditions to increase
            the [*]. Our experience has [*] that [*] is likely to be affected by
            [*] conditions. Therefore, it will be necessary to [*] of the [*] to
            [*] prior to [*] of the [*] process. [*] will initially be performed
            at [*], to [*] the effect of [*] such as [*], and [*] on [*] of [*]
            will then be [*] and further [*] with the [*].

      3.    [*]. The method of [*] used in the [*] is [*]. Alternative
            technologies for [*] will be examined. After an alternative has been
            selected, [*] will be [*] and [*] will be [*].

      Secondary Objectives

      4.    Develop [*]. In the current [*] the [*] used in the [*] are used for
            [*]. It would be [*] to use the [*] for [*], since they represent a
            [*]. The [*] will be used to [*] a [*] and/or [*] that will allow
            the [*] to be used for [*].

            5.    [*]. The volume of [*] used in the MPL(R) process may be [*]
                  by [*] and [*] that is [*] from the [*]. It will be necessary
                  to [*] the [*] from a number of lots to [*] and [*] and [*].
                  Based on this information, a [*] may be developed to allow the
                  [*] to be used in [*] and [*] will be performed with [*] to
                  determine whether there is any [*] on [*]. After [*] to the
                  [*] will need to be [*].

                                              Estimated time and FTEs

      [*]

      TOTAL: [*] FTE-YR

5.4   [*]

      [*] will be performed to increase the [*] in the [*], thereby increasing
      [*] and reducing [*]. Efforts will be applied to characterize the [*] and
      [*], so that the [*] of [*] and [*] may be assessed. The [*] MPL(R)
      derived from the [*] must be [*], with respect to [*] and [*], to [*]
      MPL(R) derived from the [*].

      Estimated time and FTEs: [*]

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              26

<PAGE>
5.5   [*]

      The current [*] process uses less than [*] of the [*] of the [*]. In the
      current process the [*] accounts for [*] than [*] of the total amount of
      [*]. Therefore, the [*] may be [*] by [*] the [*] of MPL(R).

      [*] will be performed with a goal of [*] the [*] by [*] will be performed
      on [*]. The [*] will be to develop [*] for [*] which results in a [*] that
      is [*] to that [*] by the [*]. It is [*] that the [*] results in [*] of
      [*] and [*] which may be [*] in the [*]. Therefore, [*] will be [*] to [*]
      of these [*]. It is desired to use [*] for the [*] than a [*] as used in
      the current process. Thus, [*] will need to be [*] and [*] will be [*].

      In the current process, [*] is used in the [*] for a [*]. An [*] will be
      [*], which [*] the amount of [*] used in this step.

                                                    Estimated time and FTEs

      [*]

      TOTAL: [*] FTE-YR

5.6   [*]

      [*] will be performed to [*] the [*] of the [*], as required to [*] the
      [*] of the [*] may be [*] to [*] in [*] of the [*] as a [*]. It is desired
      to use [*] for the [*] than a [*] as [*] in the [*]. Thus, [*] will need
      to be [*] and [*] will be [*].

      Estimated time and FTEs: [*]

5.7   [*]

      The current process [*] the MPL(R) into [*], followed by [*] minutes per
      [*] to [*] the MPL(R) as a [*]. This process is [*] to [*]. Some [*] for
      [*] the [*] are:

      -     [*] the MPL(R) from the [*] as the [*]. The [*] may be [*].

      -     [*] the MPL(R) from the [*] into a [*] as [*]. This [*] will [*] a
            [*] and [*] of a [*].

      -     Employ [*] to obtain a [*] of [*], allowing the [*] and [*] to be
            [*].

      -     Employ [*] to [*].

      -     If the [*] by [*] is not [*] as [*], then [*] process to [*], to be
            followed by [*].

      The first stage of [*] for the [*] step will be to [*] that will be
      acceptable, and demonstrate feasibility. The second stage will be to [*]
      the [*] for this [*].

      Corixa may [*] with [*] to [*] for [*] for [*] of TEA-MPL(R). The goal
      will be to identify a [*] that will produce a [*] TEA-MPL(R) powder, [*]
      the need for [*] in the [*]. If the MPL(R) is [*] from the [*] as a [*],
      then the [*] could [*] the [*] and [*]. When a [*] is [*] and [*], then
      [*] may decide to [*] so that [*] may be [*] the [*].

                                     Estimated time and FTEs

      [*]

      [*] TEA-MPL(R) [*]

            TOTAL: [*] FTE-YR

5.8   [*]

      The current process requires an [*]. As a result, upon [*] the [*] of the
      [*] and [*] steps the [*] and [*] steps will become the [*]. The [*] could
      be [*] with a change in [*]. The [*], with [*] of [*] per [*], is [*],
      resulting in a [*] and the [*] for the [*] that address [*]:

      Develop a [*] of the [*].

      Increase the [*] of [*] allowing a [*] in [*] to be [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              27

<PAGE>

      Switch to a [*]. This would require [*] of [*].
      Develop [*] for [*], such as [*]. The [*] may not offer an [*] for [*],
      but would allow [*] of the [*].

      Estimated time and FTEs: [*]

5.9   [*]

      Following completion of [*], approximately [*] will be performed at the
      [*] for these [*] will be at the [*]. The [*] will be [*] and a [*] of the
      [*] will be [*] using the [*]. This will be followed by [*]. Each step
      will be performed using [*] of the process. Process [*] and [*] TEA-MPL(R)
      from these [*] will be [*] by [*], as well as [*], to determine whether
      the [*] will [*].

      Additional [*] will be performed [*] to provide [*] by the [*] to [*] for
      [*]. These [*] may serve as [*].

      Estimated time and FTEs: [*]

5.10  [*]

      The [*] of the [*] is expected to require a [*] to [*]. Additional [*] are
      expected to be [*] to [*] more than [*] the [*] used in the [*]. For the
      [*] of the [*], the [*] will be [*] than [*] than used in the [*].
      Therefore, it will be necessary to [*] at [*]. The [*] will be [*] of the
      [*]. The [*] for [*] will vary for [*]. For some [*], it may not be [*] or
      [*] the [*]. Options for [*]

            Acquire [*] to allow testing at Corixa. This may [*] to [*] to [*]
            in the [*].

            Perform [*], at a [*].

            Build a [*]. The [*] could be [*] within the [*] of the [*], which
            would be [*] in [*] on [*].

      The [*] will need to be determined for [*].

      Estimated time and FTEs: [*]

5.11  [*]

      With changes in [*] and [*], it will be necessary to [*] the [*] of [*]
      will consist of [*] with the [*] for these [*] will be [*], and [*] will
      be [*] on the [*] to [*] there is any [*] with [*] of [*]. It will be
      necessary to [*] prior to [*] this [*].

      Estimated time and FTEs: [*]

5.12  DELIVERABLES - STAGE II

      Stage II [*] of the new [*] MPL(R) process at [*]. The deliverables for
      this stage are listed below and in Table 2.

      -     Development [*] for [*] at [*] to [*] for the [*].

      -     Completion of [*] at the [*].

      -     Completion of [*].

      -     Defined [*] and [*] for [*].

      -     Fully defined [*] for [*].

      -     Proposal for Stage III, including acceptable quotations for [*] from
            [*].

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              28

<PAGE>

TABLE 2. DELIVERABLES FOR STAGE II.

<TABLE>
<CAPTION>
DELIVERABLE                                                             TIMING
<S>                                                                     <C>
Development [*] for [*] at [*].                                           [*]

Completion of [*] at the [*].                                             [*]

Completion of [*].                                                        [*]

Defined [*] and [*] for [*].                                              [*]

Fully defined [*] for [*].                                                [*]

[*] for Stage III, including acceptable quotations for [*] from           [*]
[*].
</TABLE>

5.13  RESOURCES - STAGE II

      The total amount of effort to complete the tasks required for Stage II,
      based on summation of FTE effort for all individual tasks listed above, is
      [*] FTE-YR. This does not include FTEs that will be [*] for [*] at [*] (to
      be determined). As shown in the Gantt chart in Figure 1, Stage II will
      occur concurrently with Stage I. It is estimated that, assuming there are
      [*] FTEs ([*] in [*] for [*], Stage II will require approximately [*]
      years for completion. The [*] FTEs, required for completion of both stages
      I and II, may be itemized as follows:

<TABLE>
<S>                                         <C>
[*]                                         FTE
[*]                                         FTE
[*]                                         FTE
[*]                                         FTE
[*]                                         FTE
[*]                                         FTE [*]
</TABLE>

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              29

<PAGE>

[*]

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              30

<PAGE>

                                  EXHIBIT IIIB

                     COLLABORATIVE STEERING COMMITTEE (CSC)

Corixa and GSK shall agree on the installation of a Collaborative Steering
Committee (CSC) with [*] members from Corixa and [*] members from GSK. The CSC
is charged with considering and adopting or rejecting changes to the attached
Work Plan as required by the practice of good business judgment and high
scientific standards. In addition, the committee shall represent the respective
companies for current technical operations issues (MPL manufacturing, MPL
expanded capacity plans and process validation) and subsequent phase activities
as outlined in the Work Plan.

Composition: The CSC shall be comprised of [*]) named representatives of Corixa
and [*] named representatives of GSK. Each of the representatives will have one
(1) vote on matters that come before the CSC and will be entitled to vote
through proxy vote if he/she is unable to attend in person. The initial named
representatives to the CSC are as follows:

<TABLE>
<CAPTION>
Corixa Representatives                                        GSK Representatives
<S>                                                           <C>
[*]                                                                    [*]
</TABLE>

Each Party may replace one (1) or more of its named representatives from
time-to-time with the consent of the other Party, which consent shall not be
unreasonably withheld. One (1) of the representatives of Corixa shall be the
chairman of the CSC, and in such capacity, such representative shall be
responsible for setting the agenda for meetings of the CSC, with input from the
other members, and for conducting the meetings of the CSC. Each Party shall be
entitled to have further representative(s) attending CSC meetings on an ad-hoc
basis provided that such Party informs the other at least five (5) working days
prior to the concerned CSC meeting and provided that such additional
representative(s) shall have no vote on matters that come before the CSC.

Meetings: The CSC shall meet not less than four (4) times per calendar year
alternatively at Seattle, Washington, USA, Hamilton, Montana, USA and Rixensart,
Belgium or alternatively through video conferences as the CSC may agree. Subject
to the preceding sentence, the CSC shall meet on such dates and at such times
and places as agreed to by the members of the CSC. Each Party shall be
responsible for all of its own expenses relating to attendance at or
participation in CSC meetings. Within thirty (30) days following each CSC
meeting, the chairman shall cause to be prepared and shall provide to the other
Party a draft of reasonably detailed written minutes describing all matters
reviewed or considered by the CSC and all determinations or decisions made and
actions taken by the CSC and a summary of the reasons therefore stated by the
members of the meeting. The minutes of any meeting of the CSC shall be final
upon approval by the members of the CSC at any subsequent meeting. The minutes
and the drafts of any minutes shall be the confidential information of the
Parties.

Actions: For the transaction of business, a quorum consisting of at least [*] of
GSK's members and at least [*] of Corixa's members must be present at a meeting.
Decisions of the CSC, unless

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              31

<PAGE>

otherwise stated herein, shall be made by majority vote of the members, provided
that a quorum is present and at least one (1) representative of each Party votes
in favor of such action.

                                                                              32

<PAGE>

                                   EXHIBIT IV

                                Quality Agreement

                                        *

                                CORIXA - GSK BIO

                                        *

                  Supply of Bulk MPL(R) Adjuvant (MPL) for use
                          in Human Vaccine Manufacture

                                                                              33

<PAGE>

This document contains confidential, proprietary information intended for the
sole use of GlaxoSmithKline Biologicals, Inc. (GSKBio) and Corixa Corporation.
(Corixa). Disclosure of this information without the express written consent of
GSKBio and Corixa is prohibited.

Upon agreement by responsible heads of the Quality Assurance Departments for
GSKBio (Global Head Quality Assurance) and Corixa, this Quality Plan will be
revised as needed and distributed to appropriate GSKBio and Corixa personnel.

This Quality Agreement will be annexed to the supply contract and reviewed and
revised as needed.

-----------------------------------                           ------------------
Global QA Representative                                      QA Representative
GlaxoSmithKline Biologicals, SA                               Corixa Corporation

-----------------------------------                           ------------------
Date                                                          Date

                                                                              34

<PAGE>

<TABLE>
<CAPTION>
TABLE OF CONTENTS
<S>                                                                                                                <C>
1. Introduction.................................................................................................   36
2. Quality Statement............................................................................................   36
3. Standard Operating Procedures................................................................................   37
4. Personnel Training...........................................................................................   38
5. Production of Intermediates and Finished Products............................................................   39
6. Labeling and Packaging.......................................................................................   43
7. Storage and Shipping.........................................................................................   44
8. Stability Testing and Sample Retention.......................................................................   45
9. Lot Recall...................................................................................................   46
10. Change Control and Change Notification......................................................................   46
11. Quality Assurance...........................................................................................   48
12. Regulatory Issues...........................................................................................   49
13. Responsible Contacts........................................................................................   50
</TABLE>

TABLE OF APPENDICES

Appendix 1:  Corixa Documents Provided as Controlled Documents to GSK Bio

Appendix 2:  [*]

Appendix 3:  [*]

Appendix 4:  Change Notification Form

Appendix 5:  [*]

Appendix 6:  Supply Agreement Responsibilities

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              35

<PAGE>

1. INTRODUCTION

This Quality Agreement is intended to provide GSKBio, a customer of bulk MPL(R)
Adjuvant (MPL) manufactured by Corixa, with information concerning Corixa's
Quality Program. Aspects of the Quality Program that are related specifically to
the preparation, control, and handling of MPL are described within this Quality
Agreement.

The Quality Program is the responsibility of Corixa's Vice President, Quality
Systems and Compliance and involves representatives from the production,
release, control, engineering and development of Corixa's products. The VP
Quality Systems and Compliance is also the Chairman of the Specifications
Committee, which is responsible for establishing product release specifications,
and the Material Review Board, which determines the disposition of lots with
indications of possible non-conformance with established quality criteria. The
VP Quality Systems and Compliance reports to the Senior Vice President, Clinical
Development.

The objectives of Corixa's Quality Program are:

-       To assure that Corixa products are prepared in compliance with
      corporate, contractual, and national GMP regulatory standards;

-       To establish procedures that guarantee QA-oversight over product
      manufacture, testing and distribution.

-       To establish quality control procedures that enable consistent
      preparation and testing of products through control of raw materials,
      processes, equipment, personnel and test methods;

-       To establish procedures to document the performance of quality control
      measures;

-       To establish procedures to ensure the accountability of generated data,
      i.e., that the data as reported applies to the indicated processes
      measured and/or to samples submitted;

-       To establish traceability procedures for information related to product
      preparation, testing, and distribution;

-       To establish validation procedures for information related to product
      preparation, testing and distribution

-       To establish procedures that minimize the possibility of loss, damage or
      tampering with materials produced for distribution by Corixa.

2. QUALITY STATEMENT

The assurance of quality is fundamental for all work undertaken and is practiced
by all Corixa employees.

Quality is enhanced through the use of formalized procedures designed to
eliminate product deficiencies. To promote uniformity of work methods,
procedures fundamental to the production of quality materials are in effect at
all times, without significant deviation. It is the responsibility of individual
Department Managers and/or Directors to compile, implement and integrate these

                                                                              36

<PAGE>

procedures into regular working methods and to ensure that all such methods are
clearly defined and documented. It is also the responsibility of Department
Managers and/or Directors to ensure through training that employees understand
and follow procedures and to document that training.

It is the responsibility of Corixa's management to ensure that these procedures
are implemented and reviewed on a minimum of a biannual basis to assure that
they adequately reflect Corixa philosophy.

It is the responsibility of Quality Systems and Compliance to monitor the
implementation of the Quality program, to verify that necessary systems,
procedures and policies exist, or, in the absence of such, to initiate the
development of the same and to verify implementation and adherence by regular
auditing procedures.

Quality Systems and Compliance is organized such that it is free to make
decisions regarding matters of internal compliance and is not influenced either
by internal sources or by contractual sources.

3. STANDARD OPERATING PROCEDURES

Formalized documents have been developed at Corixa in the form of Standard
Operating Procedures (SOPs). These SOPs have been designed to instruct operators
on the use of equipment and the performance of specific tasks, and to describe
in-house policies intended to assure consistency of product manufacture. SOPs
have been categorized into departmental areas in which specific pieces of
equipment are used, a particular process is carried out, or in which the policy
applies. An index of the departmental sections and a brief description of the
types of SOPs contained within each section are listed below.

      Animal Care (AC) - Contains SOPs describing care, use and handling of
      laboratory animals. Animals within the facility are used both for testing
      of finished products and for research purposes by discovery and
      development departments. Quality Control maintains a separate area within
      the animal facility for housing of animals used for product testing
      purposes.

      Administration/Documentation (AD) - Contains one SOP that describes
      employee health assessments.

      Clinical/Regulatory (CR) - Contains SOPs relating to the conduct of
      clinical studies and maintenance of regulatory documentation by the
      Clinical Development Department.

      Central Supply (CS) - Contains SOPs concerning equipment used in the
      Central Supply area and policies describing the movement of materials both
      entering and leaving the Central Supply area.

      Engineering (E) - Contains SOPs describing use of metrology equipment and
      calibration of Production and Quality Control equipment with traceability
      to NIST standards. Also includes SOPs concerning operation of HVAC
      systems, water systems, electrical systems, building pressurization
      systems, and compressed gas systems. Operation of major pieces of
      production-related equipment such as autoclaves, lyophilizers and

                                                                              37

<PAGE>

      depyrogenating ovens are also covered under Engineering SOPs, as are
      procedures for equipment validation and validation of Production
      processes.

      Preventative Maintenance (PM) - Contains SOPs designed to ensure the
      continued efficient operation and care of equipment through preventive
      maintenance programs.

      Production - Contains SOPs covering cleaning and operation of equipment,
      cleaning of the Production facility, use of specialized areas within the
      Production facility, and additional instruction for processes described
      within manufacturing documents.

      Quality Control - Contains SOPs describing handling and preparation of
      samples, test methods, use and operation of equipment, and documentation
      of test results.

      Quality Assurance - Contains SOPs describing internal and external audit
      procedures, deviation reporting systems, product release, review and
      disposition of non-conforming raw materials and products, training
      policies, responding to customer complaints, customer notification of
      changes, and specification development.

      Security - Contains SOPs relating to security systems in use at Corixa.

      Shipping and Receiving - Contains SOPs describing processing and handling
      of both incoming and outgoing shipments of materials.

      Validation - Contains SOPs describing validation of computer-related
      equipment, as well as procedures related to the validation of
      manufacturing processes, testing methods and shipment procedures.

GSKBio is responsible for document control of SOPs received from Corixa. A
representative list is provided in Appendix 1.

4. PERSONNEL TRAINING

In order to ensure that personnel have the necessary education, background,
training, and experience to assure correct performance of their job functions,
Corixa selects its employees based upon education, aptitude, and experience in
the particular area for which a vacancy exists. All Corixa employees are
provided with an orientation program upon initiation of employment which covers
OSHA regulations, safety training, and GMP compliance. Orientation is tailored
for each job function by providing additional exposure in areas that are
critical to successful completion of specific job functions.

Training is an ongoing process to ensure that personnel have a thorough
understanding of their jobs. A permanent training record is kept for all
employees by each departmental Manager and/or Director. The training record
documents the in-house training as well as off-site training that an employee
has received relating to their particular job function. Job function training is
conducted both through group training sessions as well as through one-on-one
sessions with qualified trainers. Job function training is tied directly to a
particular group of SOPs as well as to the process for which the employee is
being trained. An employee is given responsibility for the

                                                                              38

<PAGE>

performance of a particular job function only after training has been completed
successfully and is documented by both the employee and the trainer.

5. PRODUCTION OF INTERMEDIATES AND FINISHED PRODUCTS

Several formalized systems have been created at Corixa to control all aspects of
the production and release of intermediates and finished products. These systems
are described by policy-related SOPs and include raw materials control, a part
numbering system that provides complete traceability of materials, and
establishment of standardized manufacturing instructions for material
preparation.

PART NUMBERING SYSTEM

All consumable materials used in the Production area are identified through a
part numbering system. An SOP is in place describing the use of the part
numbering system for identification of raw materials, in-process materials and
finished materials. Each material is assigned a five digit part number (PN)
based upon material characteristics and a Part Number Specification sheet is
prepared for that material. The Part Number Specification sheet contains
information concerning qualified vendors, material characteristics, storage
conditions, sample retention requirements, required specifications, and testing
required for proof of specification compliance. Upon receipt of raw materials,
each shipment is assigned the appropriate five digit part number and is given a
lot number in the form of an additional nine digit number based on the month,
day, and year the material is received on site and a sequential (serial) number
for the particular material. The combination of the part number along with the
nine digit numeric lot number prevents any two lots of raw material from having
the same identifier. In the same manner, a numeric lot number is assigned to
each in-process material, prepared reagent, or finished product based upon the
month, day, year, and sequential (serial) number when the manufacturing
instruction for that particular material is given to Production personnel for
initiation of production.

Part numbering coupled with assignment of lot numbers for all consumable
materials allows for complete traceability of all consumable materials used in
the production of intermediates or finished products at Corixa. The part number
assigned to MPL(R) Adjuvant at the time of signing was PN 60039. An example of a
specific lot number for MPL(R) Adjuvant is PN 60039-070999001.

RAW MATERIALS

All raw materials intended for use in production are quarantined upon their
arrival in a locked area that is accessed only by authorized Shipping and
Receiving and Quality Control personnel. An initial receiving inspection is
conducted and documented by Shipping and Receiving staff to verify that the
shipment is from an authorized vendor, the quantity ordered and the quality or
grade are appropriate as per the part number specification sheet, and the
information supplied by the vendor is accurate and complete. The shipment is
also checked by Shipping and Receiving personnel for appropriate package
integrity. A Shipping Report is completed for each lot of raw material that
documents the identity of the vendor, vendor lot number, date of arrival,
quantity, condition, and indicates the assigned Corixa part number and lot
number. This part number/lot number combination is used to identify the material
throughout its use at Corixa. A quarantine label is then affixed to each
shipping container that indicates the assigned Corixa part number/lot

                                                                              39

<PAGE>

number, the material's quarantine status, the number of units in the shipment,
and the expiration date of that lot of raw material (if applicable). The raw
material is then moved to the quarantine storage area and a Raw Material Test
Request form is completed by Shipping and Receiving staff and delivered to the
Quality Control Department along with the Shipping Report. Quality Control
representatives sample the raw material and conduct appropriate testing as
specified on the Part Number Specification sheet. Test results are reviewed, the
certificate of analysis supplied by the vendor is reviewed, and the raw material
released to Production for use only after a determination has been made that the
material meets required specifications. At that time, an overlabel indicating
that the material has been released is applied to the quarantine label by a
Quality Control representative. A copy of the Raw Material Test Request Form is
submitted to representatives of Accounting as well as to the Central Supply
clerk, and the raw material is moved to the released inventory storage area by a
Quality Control representative. The raw material is added to the released
inventory by the Accounting staff and is thereafter available for use by
Production personnel.

Tests required for the release of raw materials according to written
specifications are conducted by Quality Control prior to the release of that
material for use by the Production Department. In addition to testing by the
Quality Control Department for appropriate characteristics, a certificate of
analysis (C of A) is required from the vendor for each raw material, and that C
of A is kept on file along with all other documentation concerning that raw
material and its use at Corixa.

MANUFACTURING INSTRUCTIONS

Manufacturing instructions are prepared as master documents for the manufacture
of all materials by the Production Department at Corixa. Manufacturing
instructions are maintained under a change control system in which all changes
to procedures are evaluated, justified and approved prior to implementation.
Validation may be required prior to approval for significant changes that may
produce differences in the quality, purity, safety, and/or potency of a product.
Copies of these master documents are prepared by a representative of Quality
Assurance upon formal request by Production to initiate the preparation of
reagents, containers, closures, components, or finished products. Each
manufacturing instruction provides information concerning the requirements for
raw materials, the necessary equipment, and the procedure. In addition, the
manufacturing instructions require the operator to provide information
concerning the identification of equipment and materials used, the persons
performing the operations, the date that the operations were performed, the
yields obtained from the operation, and any further information required to
provide complete traceability of the manufacture of that material. Manufacturing
instructions are divided into four categories based upon the type of material
being prepared, as summarized below:

      Equipment Preparation Records (EPRs) provide instructions for the cleaning
      and preparation of equipment in the Production area;

      Reagent Preparation Records (RPRs) provide instructions for the
      preparation of various reagents such as media, buffers, and organic
      solvents that are used in the Production area during the manufacture of
      intermediates and/or finished products;

                                                                              40

<PAGE>

      Container/Closure Preparation Records (CPRs) provide instructions for the
      preparation of containers and closures that are used as either final
      product containers or containers for in-process materials;

      Master Batch Records (MBRs) provide instructions for the manufacture of
      intermediates and/or finished products. An individual MBR may yield an
      in-process material, or may yield the final product.

Each manufacturing instruction in place at Corixa corresponds to a part number
that identifies the resulting product. A part number specification sheet is
prepared for each part number assigned that contains all information regarding
the material manufactured (see above). As copies of manufacturing instructions
are issued by Quality Assurance to Production personnel for the initiation of a
manufacturing procedure, a lot number is assigned to that copy of the
manufacturing instruction according to the day of the month and the year that
the work order is processed by Central Supply personnel. That part number/lot
number combination is used to identify the manufactured material and to trace it
throughout its existence.

Completed manufacturing instructions for each reagent, in-process intermediate,
container/closure preparation, intermediate, or finished product are reviewed by
a representative of Quality Assurance as the material is submitted to Central
Supply for quarantine. Once reviewed, the manufacturing instruction document is
stamped to indicate completion of the review and initialed by the reviewer. If
any deviations from written instructions have occurred during the manufacturing
process, a deviation report is prepared and submitted to the QA Manager for
review. A determination as to whether that deviation might have an effect on
product quality, purity, safety, or potency is either made by Quality Assurance
or deviation reports may be forwarded to the Material Review Board for review
and determination of disposition of the material. GSKBio will be notified of any
deviation investigations carried out during the manufacture of a product that is
intended for delivery to them via the Tracking Transfer Document.

The Quality Control Department at Corixa is responsible for testing as well as
the release or rejection of raw materials, packaging materials and in-process
materials based on current specifications. Laboratory facilities and equipment
are appropriate for the required analytical procedures, and personnel have been
sufficiently trained to perform the analyses accurately. Operator training is
documented as per the requirements of the training program. Maintenance and/or
calibration procedures, including system suitability evaluations if applicable,
are included for analytical equipment and assays. Records are kept for all
reagents, culture media, and equipment used for testing purposes. Reagent
preparation is documented according to written procedures and reagents are
labeled appropriately and assigned expiration dates prior to storage in the
Quality Control laboratory.

All testing procedures carried out in the Quality Control Laboratory are
conducted according to SOPs (see Section 3). Any deviations from SOPs are
reported and investigated according to set procedures and time frames. QA is
responsible for review of such investigations, for determinations as to whether
product quality may be affected by the deviation, and for final disposition of
the product affected by the deviation.

                                                                              41

<PAGE>

MANUFACTURING DEVIATIONS

Manufacturing deviations are documented and investigated based on Corixa
controlled documents on the handling of deviations. Deviations are consistently
evaluated for any impact on the quality, purity, safety, and/or potency of the
product.

      Deviation and Observation Reporting System Forms (DORS) provide details of
      any deviation or observation of unusual manufacturing conditions (also
      provides details of any deviation/observation outside of manufacturing
      area. and includes documentation of all assessments, investigations,
      decisions and subsequent corrective actions. The DORS Event number is
      referenced on the batch record documentation. The original document is
      stored in the associated DORS Event file.

      Out of Specification Reports (OOS) provide details of any failure of the
      product to meet defined specifications and includes documentation of all
      assessments, investigations, decisions and subsequent corrective actions.

      Environmental Deviation Reports (EDR) provide details of any failure of
      the production environment to meet defined specifications and includes
      documentation of all assessments, investigations, decisions and subsequent
      corrective actions. None of these documents (DORS, OOS, EDR) become
      permanent parts of the associated batch record Corixa standard operating
      procedures prohibit the release of materials until all deviations have
      been resolved.

      Corixa QA is to decide the final status of the materials following
      appropriate investigations and assessments. GSKBio QA requires full
      transparency around any individual deviation affecting MPL- product,
      testing or shipment.

LOT RELEASE TESTING

Final products are tested according to current release specifications as listed
on part number specification sheets for each material requiring testing. Quality
Control personnel analyze the material, document the test results on the Quality
Control Analysis Report form, and attach all hard data to the form. Once testing
is completed, the Quality Control Analysis Report form and all hard data are
reviewed by the Quality Control Manager. The testing data is forwarded to the
Quality Assurance Manager for final accept/reject decisions based upon testing
results as well as review of all manufacturing documentation including
deviations from procedures. If the final product meets all release
specifications and has been manufactured according to required procedures with
no significant deviations, a notification of release is provided to Central
Supply by Quality Assurance to indicate release. Finished product is then
removed from the Central Supply quarantine area to the finished goods area by
Central Supply personnel.

If the finished product does not meet release specifications, a procedure (SOP)
is in place to track the disposition of the rejected material. A Material
Rejection Report is completed by Quality Assurance and that report is circulated
to representatives of Production, Adjuvant Development, Purchasing and Quality
Control for signature. A copy of the completed Material

                                                                              42

<PAGE>

Rejection Report indicating disposition of the rejected material, is provided to
Accounting and the rejected material is disposed of appropriately.

GSKBio will perform lot release testing upon receipt of MPL materials, according
to GSKBio Quality Control Procedure 10026402 (Appendix 5). GSKBio will make
their acceptance criteria and methods for determining acceptability available to
Corixa. They will also advise Corixa of any changes in their requirements or
methods.

If the received bulk materials are found to not comply with the agreed
specifications, GSK will notify Corixa immediately, advising Corixa of the batch
number(s) and such details of the test failure as are available. After
confirmation of the GSKBio testing result, Corixa shall retest samples from the
same bulk retained. If Corixa finds that, based on the retested sample, the bulk
does not comply with the specifications set forth in the Corixa material
specifications, it will be treated as if no lot had been delivered and a
replacement lot will be scheduled in accordance with the supply agreement.

In the case that Corixa results and GSKBio results on the suspect lot do not
match, and after a reasonable investigation on the reason for the opposing
results Corixa, a mutually agreed third party shall continue testing of the
suspect lot and decide on the questioned compliance with the set specifications.
Corixa and GSKBio will share equally the costs associated with the third party
testing including any costs associated with the necessary technology transfer.
At the discretion of either party, this requirement may be waived and the
opposing parties position accepted without any admission of fault.

6. LABELING AND PACKAGING

Labeling of materials is strictly controlled through a series of SOPs that
describe the requirements for documentation and control, label accountability,
performance of labeling operations, and inspection of labeling areas prior to
and following labeling operations. All incoming labeling materials are placed in
quarantine by Shipping and Receiving personnel pending examination of
representative samples against an approved master copy of that item by Quality
Control. A record of receipt, examination or testing, acceptance or rejection,
and disposition is kept for each shipment of labeling materials. Each individual
type of labeling material has been assigned a part number and a part number
specification sheet prepared with appropriate information including a master
copy of the labeling material. A lot number is assigned to the labeling material
based upon the date that it arrives on site.

All labeling materials are stored in a secured storage area with labels for
different products stored separately.

A labeling operation is initiated by a request from a Production representative
for labeling materials. A "Label Accountability" form is prepared that documents
the number of labels issued, 100% inspection of those labels by two persons for
conformity to master label stock, and use of those labels during labeling
operations. Labeling operations themselves are controlled by SOPs requiring
documentation of the use of the labels as well as requiring inspections of pre-
and post-labeling operations by a representative of Quality Control.

Corixa will notify GSKBio of labeling changes affecting MPL.

                                                                              43

<PAGE>

7. STORAGE AND SHIPPING

MPL final product is filled and lyophilized in 1 L screw top bottles composed of
USP Type 1 borosilicate uncolored glass. The fill quantity is 2 g per bottle and
the bottles are stoppered under a nitrogen gas overlay. The bottles are closed
with 43 mm lyophilization stoppers made of gray butyl rubber (4416/60 gray
formulation). Bottles plus stoppers are capped with plastic screw caps and are
sealed with tamper-proof seals.

MPL is also provided in 10 mL vials with 5 mg per vial for Quality Control
testing at Corixa and GSKBio. The vials are made of USP Type 1 borosilicate
uncolored glass and are closed with 20 mm lyophilization stoppers consisting of
gray butyl rubber (formulation 850). Vials plus stoppers are capped with 20 mm
aluminum tear-off seals.

A shipment of MPL is initiated with receipt of a purchase order from GSKBio and
is based upon availability of inventory as well as prior agreements between
GSKBio and Corixa. MPL is delivered to GSKBio FOB from the Corixa facility in
Hamilton, MT, or at other locations as Corixa may specify. Title to and risk for
the MPL shipment passes to GSKBio upon delivery to the freight carrier.
Shipments of MPL are handled by Federal Express International carrier or
equivalent and will be designated as "international priority" mail.

All shipping procedures for MPL are described and controlled in SOPs (see
Section 3). The specified shipping containers hold up to 6 x 2 g bottles of
MPL,. The bottles are wrapped individually with protective packing material
prior to placement in the container. Frozen ice packs are included with each
shipping container to maintain a specified temperature range throughout the
course of the shipment. Corixa will use validated shipping configurations to
guarantee the temperature and seal of the materials during their transfer to
GSK-premises.

Depending on the quantity of MPL that has been ordered, a shipment may comprise
more than one shipping container and more than one lot of MPL. The container
designated as "#1 of N" will contain the following items:

1.    For each lot of MPL in the shipment, a Release Protocol that provides
      testing results and release authorization by the Quality Assurance Manager
      (Appendix 2);

2.    For each lot of MPL in the shipment, a Tracking Transfer Document that
      contains a deviation summary, as well as a summary of any manufacturing
      changes, information on lot numbers, yields, and test results for the
      in-process intermediates used in manufacture of the lot, along with
      process information on key steps (Appendix 3);

3.    For each lot of MPL in the shipment, 30 x 5 mg vials for Quality Control
      testing and retention. In the event that a lot of MPL has been shipped
      previously to GSKBio, no 5 mg sample vials will be included unless prior
      arrangements have been made by GSKBio;

4.    Standard shipping documentation for international shipment of materials as
      required by the carrier as well as the appropriate customs office.

A TempTale monitor will also be included in each container along with
instructions for returning the monitor(s) to Corixa. The monitor(s) will be
programmed to record temperature at 5 minute intervals throughout the entire
shipping period.

                                                                              44

<PAGE>

Upon arrival of the shipment at the premises of GSKBio or of their specified
agent, the following procedures will be performed:

1.  Containers will be inspected for damage and enclosed documentation
      evaluated for completeness;

2.  The TempTale monitor will be removed from each container, date stamped (by
      depressing the date stamp button on the end of the unit without the silver
      ring), and the data will be downloaded. The monitor(s) are to be returned
      to Corixa, and must be received by Corixa within 20 working days from
      delivery of the shipment;

3.  The Receiving Report form from container #1 will be filled out and filed
      by GSKBio; 4. The Transfer Document(s) and Certificate of Analysis(es)
      will be removed from container #1 and distributed to the appropriate
      personnel at GSKBio;

5.  The 5 mg sample vials will be removed from container #1 and given to a
      representative of Quality Control;

6.  Bottles containing MPL will be removed from the shipping containers and
      placed in storage at 2(Degree)-8(Degree)C.

Temperature data from the TempTale monitors are to be reviewed by a designated
representative of GSKBio. Should it be determined that a temperature excursion
involving exposure to temperatures outside the specified range of for a period
exceeding one hour has occurred, GSKBio will notify Corixa and the disposition
of the affected container(s) will be determined by joint discussions. GSKBio is
responsible for archiving the temperature data for all shipments.

8. STABILITY TESTING AND SAMPLE RETENTION

The Quality Control Department at Corixa will maintain and execute a master
stability protocol for MPL, as described in SOP QC-10039, "Master Stability
Protocol for MPL(R) Bulk Drug Substance." According to this protocol, expiration
dating for MPL is established by real time stability testing on three lots of
MPL. Thereafter, one lot of MPL per year is selected at random to be enrolled in
the stability program. The first three lots manufactured after marketing
approval is received will also be placed on real time stability, followed by one
lot per year in subsequent years.

GSKBio will be notified in the event that any lot of MPL received by them fails
a real time stability test. Such test failures require an investigation to
determine if the test result is valid, and notification of GSKBio will occur
within 3 days of completion of such determination. GSKBio will also be notified
if information emerges which indicates that the shelf life for MPL is incorrect.
These communications will occur through GSKBio Quality Assurance.

The Quality Control Department at Corixa will retain a supply of 5 mg and 10 mg
sample vials from each released lot of MPL. These retention samples will be
stored at 2(degree)-8(degree)C, in the same manner as for the product, and will
be used in the event that unanticipated questions arise requiring further
testing and/or characterization. If adequate supplies are available, retention
samples may be provided to GSKBio as necessary to assist in their investigation
of lot-related questions.

                                                                              45

<PAGE>

9. LOT RECALL

The procedure for recall of marketed products by Corixa is described in SOP
QA-9900, "Marketed Product Recall." This SOP describes the process for making
product recall decisions, and also delineates the actions following a recall
decision, including retrieval of distribution data, notification of customers,
receipt/segregation/inspection of returned product, investigation/reporting of
returned product, and reporting of corrective actions.

Recall decisions are initiated by a recommendation from the Material Review
Board, which is chaired by the VP Quality Systems and Compliance or their
designee. This recommendation is reviewed by a senior management team at Corixa.
In the event that there is a recommendation to recall one or more batches of MPL
or to recall other formulations of MPL that could implicate the MPL, GSKBio QA
will be notified the same working day.

Final responsibility for all recall decisions resides with the CEO/President of
Corixa. The Regulatory Affairs Department is responsible for coordinating recall
actions.

GSKBio is responsible for the recall of any affected lot(s) of their product(s)
that contain the recalled lot of MPL. GSKBio is also responsible for notifying
the appropriate regulatory authorities of the recall actions related to their
products.

10. CHANGE CONTROL AND CHANGE NOTIFICATION

Changes to procedures, processes, equipment, test methods, and specifications
related to MPL manufacture, testing and shipment as well as other GMP products
made by Corixa are strictly controlled by Corixa's change control and change
notification policies. GSKBio will have access to Corixa's Change control policy
procedure. As a customer of Corixa, GSKBio will be notified of any changes
related to the manufacture, testing and shipment of MPL. Procedures related to
Corixa's change control policy are described in SOPs E-1004 (equipment), QA-100
(controlled documents), and QA-3501 (specifications), and the customer change
notification policy is described in SOP QA-104. These SOPs are incorporated by
reference in this Quality agreement, and controlled copies of these documents
will be provided to GSKBio and maintained in accordance with Corixa's document
control procedures. The main elements of the customer change notification policy
(SOP QA-104) are summarized in this section.

POLICY STATEMENT

Corixa recognizes the value of its customer, GSKBio, and the importance of
communication in maintaining a satisfactory business relationship. In
recognition of Corixa's commitment to customer satisfaction, Corixa agrees to
notify GSKBio in a timely and appropriate manner of all changes relating to the
manufacture and release of MPL. The timing and manner of notification, as well
as the level of involvement by GSKBio prior to implementation, will be
determined by the category of change as specified in this policy.

PURPOSE

As a producer of MPL, Corixa must occasionally make changes in its processes to
ensure that this product continues to meet the needs of its customer, GSKBio. At
the same time, GSKBio must be confident that such changes will not compromise
the performance and suitability of

                                                                              46

<PAGE>

MPL for use in its applications. The purpose of this policy is to provide a
mechanism for addressing the needs of both Corixa and GSKBio regarding changes
affecting MPL. This policy defines procedures by which GSKBio will be informed
of all changes in the manufacture, release, and control of MPL.

PROCEDURE

The FDA recognizes that changes differ with respect to their potential to
adversely affect the safety, purity, and/or potency of a product, and
accordingly have established different reporting requirements for changes
depending on their level of importance. Corixa applies the reporting
requirements for the FDA to notification of GSKBio to changes related to MPL.
The change notification categories and procedures used by Corixa are summarized
below (additional detail is provided in SOP QA-104):

      Category 0 - Editorial Changes - This category involves changes that do
      not alter the process or product per se but relate only to documentation
      changes that are considered editorial. Such changes will generally not be
      reported to the regulatory authorities unless they involve the Drug Master
      File or other regulatory filings. Category 0 changes will be communicated
      to GSKBio by notation on the documentation that accompanies the first
      affected lot. GSKBio approval is not required for implementation of
      Category 0 changes.

      Category I - Minor Changes - These changes include modifications to
      procedures, process parameters, components, manufacturing methods,
      reagents, equipment and facilities that are intended to tighten control(s)
      on the product or process and yet are not associated with a potential
      adverse impact on product safety, purity or potency. Limited qualification
      or validation may be required for Category I changes. Such changes will
      typically be reported to the regulatory authorities in the form of routine
      annual reports, and it may be necessary to amend regulatory filings as a
      result of such changes. All Category I changes will be communicated to
      GSKBio via the Change Control Form (see Appendix 4). GSKBio approval is
      not required for implementation of Category I changes.

      Category II - General Changes - Changes in this category include
      modifications that do not change the manufacturing process for MPL but
      have the potential to adversely affect product safety, purity and/or
      potency. Changes in test methodology or product specifications intended to
      tighten control are also included in this category. Corixa will notify
      GSKBio of Category II changes. Notification will be made via a package
      comprising the Change Notification Form, supporting documentation, and
      test samples as appropriate. Implementation of Category II changes
      requires written agreement by GSKBio within 30 days of receipt of the
      change notification package unless alternative arrangements have been
      made. It is the responsibility of GSKBio to obtain required authorities
      approval for implementation of proposed changes. Final approval of a
      change by competent authorities will be communicated by GSKBio to Corixa
      in a timely manner.

      Category III - Major Changes - Changes in this category are considered
      significant and will require process validation. The implementation plan
      for such changes will typically be discussed in advance with GSKBio and
      should include provisions for process validation and demonstration of
      product/process consistency. Corixa will provide

                                                                              47

<PAGE>

      GSKBio with a package comprising the Change Notification Form, supporting
      documentation, and test samples as appropriate. Implementation of Category
      III changes requires written agreement by GSKBio within 90 days of receipt
      of the change notification package unless alternative arrangements have
      been made. It is the responsibility of GSKBio to obtain required
      authorities approval for implementation of proposed changes. Final
      approval of a change by competent authorities will be communicated by
      GSKBio to Corixa in a timely manner.

      Category IV - Unanticipated Manufacturing Changes - Such changes may occur
      due to equipment failure, damage to facility, loss of suppliers of
      critical raw material, and other unforeseen events. Such changes will be
      communicated to GSKBio at the earliest possible time and in all cases in
      advance of product shipment. Changes involving general and routine
      equipment maintenance are not included in this category.

All official communications relating to changes will be conducted between the
respective QA representatives at Corixa and GSKBio. The QA representatives are
responsible for transmitting all change notification issues to appropriate
personnel at their respective companies for input and/or action, and for
notifying the other company of any further actions required as a result of these
communications.

For changes requiring prior notification, Corixa will discuss the proposed
changes with GSKBio in a time frame that encourages cooperation and allows for
the needs of both parties to be met. These discussions will establish the
category of the change, the necessary level of documentation, the appropriate
degree of involvement by GSKBio in the approval process, and the inventory
requirements for "pre-change" product. A detailed implementation plan may be
developed that defines the testing and validation required for approval of the
change. All contractual obligations of Corixa regarding the supply of MPL to
GSKBio will remain in effect throughout any change period, unless specific
exceptions have been agreed to by Corixa and GSKBio.

Corixa's change control procedures require that documentation be maintained in
support of all changes in manufacturing processes, equipment, test methods and
product specifications. Corixa will allow access to such documentation related
to MPL during facility audits conducted by GSKBio. GSKBio maintains a "right to
audit" of Corixa developmental documents and validation reports prior to
acceptance (approval) of general and major changes that affect MPL, or
retrospectively in the case of unanticipated changes.

11. QUALITY ASSURANCE

Upon request from GSKBio, the Quality Systems and Compliance Department at
Corixa will provide information necessary to demonstrate that appropriate
quality systems are in place and are adhered to during the manufacture and
release of MPL. GSKBio may gather such information in part through scheduled
audits of the Corixa facility.

The Quality Systems and Compliance Department at Corixa has responsibility for
the review and release of all finished lots of MPL. All lots of MPL must be
released before shipment to GSKBio or its agent. All product complaints related
to MPL should be directed to the VP Quality Systems and Compliance at Corixa.

                                                                              48

<PAGE>

Process and product deviation for any lot/batch will be notified by Corixa to
GSKBio in advance of delivery and full technical discussion will take place
between the two parties with full exchange of information to take appropriate
measures and find best solutions.

The Quality Systems and Compliance Department will prepare a Release Protocol
and a Transfer Tracking Document to accompany each lot of MPL that is shipped to
GSKBio. The Certificate of Analysis contains a summary of the test results and
indicates the date of release of the lot. The Transfer Document provides a
summary of all manufacturing changes, information on lot numbers, yields, and
test results for the in-process intermediates used in manufacture of the lot,
along with process information on key steps (See also Section 8.)

Trending of yields, process times, and analytical results will be performed on
critical process points and quantitative test results as determined by the
Quality Systems and Compliance Department at Corixa. The Quality Systems and
Compliance Department will notify GSKBio of results from any trend analysis that
indicate that the MPL manufacturing process is operating outside of historical
ranges.

A GMP statement signed by Quality Assurance representative has to be provided
with every lot together with the certificate of analysis.

12. REGULATORY ISSUES

Corixa maintains a Type II Master File (MF) with the Center for Biologics
Evaluation and Research at the FDA. This MF was initially submitted on October
29, 1992, and is identified as BB-MF 4809, "Manufacture and Control of
Monophosphoryl Lipid A, a Drug Substance." BB-MF 4809 has been amended as needed
to accurately document the manufacture and control of MPL. The most recent
amendment to the MF was Amendment #5 and was submitted on June 20, 2003. The
Regulatory Affairs Department at Corixa will provide GSKBio Regulatory Affairs
with an updated copy of BB-MF 4809 as well as any amendments to this MF.

The Regulatory Affairs Department at Corixa will provide GSKBio with regulatory
support as necessary for development and licensure of GSKBio final products in
which MPL is a constituent. Corixa Regulatory Affairs will respond to requests
from the FDA and other regulatory authorities for information related to MPL,
and will notify GSKBio Regulatory Affairs in a timely manner of any such
discussions that potentially affect the use of MPL by GSKBio. Corixa Regulatory
Affairs will cooperate with GSKBio Regulatory Affairs in support of all
regulatory filings involving MPL, including participation in meetings with
regulatory authorities as appropriate.

GSKBio is ultimately responsible for ensuring the accuracy of any information
related to MPL that is contained in its regulatory filings.

                                                                              49

<PAGE>

13. RESPONSIBLE CONTACTS

[*]

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              50

<PAGE>

APPENDIX 1. CORIXA DOCUMENTS PROVIDED AS CONTROLLED DOCUMENTS TO GSKBIO

<TABLE>
<CAPTION>
SOPs
<S>                <C>
#CS-400            Assigning Lot Numbers
#CS-551            Label Documentation and Control
#E-1004            GMP Equipment Change Control
#P-530             Labeling Operation Procedure
#QA-100            Controlled Document Change Control
#QA-104            Customer Change Notification Procedure
#QA-2000           Deviation and Observation Reporting System
#QA-2001           Material Rejection
#QA-2002           Customer Complaint Procedures
#QA-6000           Material Review Board Operation
#QA-9000           Batch Record Review and Product Release
#QA-9001           Issuance, Distribution and Control of Manufacturing Instructions
#QA-9003           Preparation of GlaxoSmithKline Tracking/Transfer Documents
#QC-981            Raw Material Quality Control Procedure
#SR-001            Receiving Procedures
</TABLE>

                                                                              51

<PAGE>

APPENDIX 2. [*]

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              52

<PAGE>

APPENDIX 3. [*]

                                              *CONFIDENTIAL TREATMENT REQUESTED.

                                                                              53
<PAGE>

APPENDIX 4. CHANGE NOTIFICATION FORM

                                                                  SOP #QA-104.01
                                                                   Attachment #1
                                                                     Date: 03/02
                                                                 Supersedes: #NA
                                                                     Page 6 of 7

                            CHANGE NOTIFICATION FORM

PART A - NOTIFICATION BY CORIXA CORPORATION

Notification ID Number:______                  Change Control ID No:______

Change Category:______   Change Control Date:______   First Affected Lot:______

AFFECTED COMPONENT(S) [include Corixa ID number(s) and brief description(s)]

DESCRIPTION OF CHANGE(S)

REASON FOR CHANGE(S)

VALIDATION/QUALIFICATION

[ ]   Necessary - describe validation/qualification study and result (attach
      relevant materials)

[ ]   Not Necessary - provide justification

CORIXA QUALITY ASSURANCE

Name: _________________________________________

Title:_________________________________________

Signature/Date: _______________________________

                         "CONTROLLED COPY" (Red Print)

                                                                              54

<PAGE>

                                                                  SOP #QA-104.01
                                                                   Attachment #1
                                                                     Date: 03/02
                                                                 Supersedes: #NA
                                                                     Page 7 of 7

PART B - RESPONSE BY CUSTOMER (CATEGORY II AND III CHANGES ONLY)

Notification ID Number:______                Change Control ID No.______

Change Category:______   Change Control Date:______     First Affected Lot:_____

CUSTOMER RESPONSE AND COMMENTS

[ ]   Approved

[ ]   Not Approved - please provide detailed explanation

CUSTOMER REPRESENTATIVE

Name: _____________________________________

Title:_____________________________________

Signature/Date: ___________________________

                         "CONTROLLED COPY" (Red Print)

                                                                              55

<PAGE>

APPENDIX 5:[*]

                                                                              56

                                               *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

APPENDIX 6: SUPPLY AGREEMENT RESPONSIBILITIES

                                                                  Responsibility
1.

<TABLE>
<CAPTION>
                                                                                                   Responsibility
                                                                                                   --------------
        Clause                                                                                     Corixa     GSK
        ------                                                                                     ------     ---
<S>                                                                                                <C>        <C>
1       Manufacture of the MPL Bulk Product and release for use in GSK vaccines                     X

2       Starting raw materials are purchased, tested and released by                                X

3       Expiry dating, batch numbers and storage conditions will be provided by                     X

4       Safety information to be provided by                                                        X

5       Starting raw materials retention samples held by                                            X

6       Final bulk product retention samples held by                                                X

7       Stability testing on bulk products to be done by                                            X
        Stability testing on final vaccines to be done by                                                      X

8       Records of manufacturing and testing of bulk to be held by                                  X

9       Certificates of analysis and GMP statement of bulk product to be prepared by                X

10      Final inspection and reconciliation of bulk product by                                      X

11      Storage in Corixa warehouse                                                                 X

12      Packaging and placing of suitable shipment monitoring devices by                            X

13      Validation of shipment operations by                                                        X

14      Storage in GSKBio warehouse                                                                            X

15      Recall decision on unsuitable bulk                                                          X          X

16      Shipment of recalled bulk by                                                                           X

17      Investigation on pharmaceutical technical complaints (PTC's) relating to bulk product:
        Initial complaint                                                                                      X
                              Manufacturing and testing of bulk                                     X
                              Effectiveness stability and safety of bulk                            X
                              Reply to complainant                                                             X

18      Investigation on Medical Complaints relating to bulk product:

                              Initial complaint                                                                X
                              Clinical Investigation                                                           X
                              Technical Investigation                                                          X
                              Serious and unexpected adverse Events to Corixa within 7 d                       X
                              Vaccine product recall and report to Corixa                                      X

        Investigation of complaints related to the bulk MPL product                                 X

19      Recall or market withdrawal
        Initiation of recall related to the vaccine product                                                    X
        Notification to Corixa within three working days                                                       X
        Disposition of lots for further technical investigation                                     X          X

20      Error and Accident Reporting
        Report to Corixa of inadvertant storage or transport of bulk                                           X
        Decision regarding further disposition of affected bulk product                             X          X
</TABLE>

                                                                              57

<PAGE>

<TABLE>
<CAPTION>
                                                                                                  Responsibility
                                                                                                  --------------
        Clause                                                                                    Corixa     GSK
        ------                                                                                    ------     ---
<S>                                                                                                <C>        <C>
21      Lot Tracing
        Generation of comprehensive traceability records for bulk                                   X
        Generation of comprehensive traceability records for vaccine                                           X

22      Where manufacture of vaccine finished product is carried out by third parties,
        GMP-responsibility is assumed by                                                                       X

23      Alterations to the contract, specifications and manufacturing or testing procedures shall
        be agreed in writing                                                                        X          X

24      Master packing and labeling instructions
        Provided by                                                                                            X
        Prepared by                                                                                 X
        Agreed by                                                                                   X          X

25      Annual Quality Report of Product Quality Review including production                        X
        overview, quality results overview, stability, complaints to be
        provided to GSK.                                                                            X

26      Receipt testing and acceptance of bulk MPL adjuvant after shipment                                     X
</TABLE>

Signed on behalf of Corixa/ date

Signed on behalf of GSKBio/date

                                                                              58

<PAGE>

                                    EXHIBIT V

                    MANUFACTURING KNOW HOW TRANSFER WORK PLAN

                                  (LEFT BLANK)

                                                                              59

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00073-of-00352.parquet"}]]